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PREFACE 
 
A mini thesis submitted to the School of Health Sciences, Discipline of Pharmaceutical 
Sciences, University of KwaZulu-Natal, Westville Campus, for the partial fulfilment of the 
degree of Master of Pharmacy (Pharmacoeconomics). This is a mini thesis in which the 
chapters are written as a set of discrete research manuscripts, with an overall introduction, 
literature review, and final summary. The findings of the study are presented in chapter 3, as 
a manuscript as required by the regulations of the University of KwaZulu-Natal. This 
manuscript has been submitted for publication to the Journal of Pharmaceutical Health 
Services Research. The reference list is cited according to the instructions for authors as 
required by the Journal of Pharmaceutical Health Services Research. A complete reference 
list is included at the end of every chapter. 
 
The dissertation consists of four chapters as follows: 
Chapter 1: provides an introduction to the study as well as the aims, objectives, and a brief 
overview of the methodology. 
Chapter 2: provides the literature background to the study. 
Chapter 3: consists of the results, discussion, and conclusion written in a manuscript format. 
Chapter 4: provides the general conclusions, recommendations, limitations, and strengths of 
the study. 
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ABSTRACT 
 
Introduction 
The adoption of medicine pricing regulations was established to counter the on-going global 
struggle of high medicine prices. South Africa’s healthcare is divided into the private and 
public sector and each sector functions utilizing different medicine pricing systems i.e. the 
tender and single exit price (SEP) system. The National Health Insurance (NHI), in its pilot 
phase in SA, may declare new system changes and improvements. Therefore, increased data 
on current medicine pricing systems are necessary particularly to assist the NHI process. 
Aim 
The overall aim of this study was to compare the medicine prices procured in the public 
tender system with the private SEP system. 
Objectives 
The objectives of the study were to compare pricing trends, determine price differentials, 
and equate the average price index of a basket of medicines between the public and private 
healthcare sectors in South Africa. 
Methods 
A pricing list consisting of 32 essential medicines available in both the public and private 
healthcare systems of South Africa was chosen for this study. The price of medicines for the 
private sector were obtained from the Medicine Price Registry- Open Up website for the 
period 2014–2018. Public sector medicine prices were obtained from the Department of 
Health website for the corresponding period. Observations and pricing trends were identified 
and analysed using Microsoft Excel version 2016. 
Key Findings 
A total of 74 medicine brands were analysed in the study. It was found that the prices across 
both sectors had increased over time, however, the majority of brands (87%) displayed 
higher prices in the private sector in comparison to the public sector. The price differential 
between the private and public sector medicines yielded positive values with the median of 
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252.30%. 
Conclusion 
The study found vast price differences between each pricing system due to the different 
methodologies practiced. Some of the methods and procedures utilized are known, however, 
both systems lack complete transparency in the processes applied. Therefore, more 
transparent medicine pricing systems need to be considered for the future of South Africa’s 
healthcare system as the country transitions toward universal health coverage. 
Keywords 
Public tender prices, single exit price (SEP), medicine pricing trends 
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CHAPTER 1: INTRODUCTION 
Medicine accessibility and availability is a continuous global challenge and concern (World 
Health Organization and Health Action International, 2008). Coupled with an increase in the 
price of daily resources, medicine expenditure is also on the rise. Globally, there have been 
several efforts to decrease medicine prices and increase accessibility to medicines. Amongst 
these efforts has been the introduction of medicine pricing policies which aims to regulate 
medicine prices thus resulting in improved accessibility and availability of medicines. 
The private healthcare sector of South Africa (SA) utilizes pricing regulations in the form of 
the Single Exit Pricing (SEP) system, which regulates medicine prices for this sector. The 
public healthcare sector of SA is largely government-funded and utilizes a medicine tendering 
system to avail medicines. These two systems currently function in parallel with its respective 
concerns, however, with the National Health Insurance (NHI) being in its pilot phase in SA, 
confirmation on the pricing regulations to be used are still malleable. Research on the impact 
and use of current pricing regulations is limited and requires further investigation to assist in 
forecasting trends and policy requirements for the future healthcare system in SA. 
This thesis aims to present the pricing trends between the two medicine pricing systems by 
comparing the prices of specific essential medicines over the preceding five years (2014 - 
2018). The current and archived medicine price data were collated to establish the trends 
that exist in each sector. Observing these trends will provide perspective on the current 
mechanisms practiced in each pricing system and aid policymakers in future projections for 
South Africa’s healthcare system. 
1.1 Background and Rationale Behind the Study 
The need for bettering healthcare systems is a priority among most countries worldwide. 
Systems that can develop and improve the pharmaceutical division are imperative in order 
to establish sustainable and favourable mechanisms. Several methodologies are thus being 
applied and investigated to accomplish accessibility as well as the availability of medicine 
to all citizens as a vital outcome.
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The Essential Medicine Lists (EML) is in place to support access to basic medicinal products 
at adequate pricing, quantity, and quality, in the effort of making medicines available for 
both the individual and communities at large (World Health Organization, 2019). Access to 
these medicines ensures that the basic human right to healthcare is prioritized. The efforts of 
such practice are to ensure that the majority of the population have access to essential needs 
in a pharmaceutical society where decreased medicine prices are difficult to obtain (van der 
Gronde, et al., 2017). South Africa’s public health sector utilizes the EML with the intent to 
provide access to the most vital medicinal needs. The procurement of medicines from the 
EML is done via the medicine tender process and relies on pharmaceutical companies 
bidding toward the tender contract for specific medicines (Department Health Republic of 
South Africa, 2020). 
The private healthcare sector does not utilize an EML ( medicine formularies are more often 
used to regulate spending in this sector)_, however, pricing regulations were established to 
achieve some standardization in relation to medicine pricing for this sector. Several 
regulations in the private sector were implemented to improve access to medicines at 
affordable prices. One such regulation was the SEP system. The SEP system mandates that 
the cost of a medicine is sold at a standard price to all consumers (except for the government) 
as decided by the manufacturer, irrespective of the quantity ordered by the customer as well 
as the consumption levels used (Bangalee & Suleman, 2018). However, the measures of 
success of pricing policies and regularities remain multi-dimensional and complex, hence 
necessitating for further investigations of the current pricing regulations (Bangalee & 
Suleman, 2015). 
The pricing systems currently employed need to exhibit better transparency and consistency 
in prices throughout the public and private sectors especially with the implementation of the 
NHI. The procurement processes utilized in the current healthcare system do not function 
uniformly thus leading to the inconsistency of prices of the same medicinal products in the 
different sectors. Information concerning current pricing policies and its effects on medicinal 
prices are vague and require more investigations before conclusive decisions about the 
functionality of each pricing system can be made. Further understanding of the current 
medicine pricing systems existing in contrast to each other forms the cornerstone and 
foundation of this study. 
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1.2 Aims and Objectives 
The overall aim of this study was to compare the medicine prices procured in the public tender 
system with the private SEP system. This thesis has the following specific objectives: 
• To examine the prices of medicines in the public and private sectors to establish the pricing 
trends that exist 
• To determine the medicine price differential between each pricing system 
• To equate the average price index between each pricing system 
 
1.3 Significance of the Study 
The medicinal procurement systems in use face constraints due to “lack of financial oversight, 
insufficient communication, and liaison between stakeholders; poor procurement practices; 
outdated information systems and lack of human resources to support the current system” 
(Berger, et al., 2010). Further investigation within each medicine pricing system is necessary 
due to many problems that are encountered by each system. The South African government 
has employed medicine pricing policies and regulations with the intent of decreasing the 
medicine cost burden faced by the citizens of SA. The high cost of medicine is one of the many 
challenges that affect the progress of healthcare and disease management and requires an 
efficient system to be implemented to address these challenges. The National Drug Policy 
(NDP) initiated the medicine pricing regulations to improve the healthcare system in SA. 
However, with trying to improve healthcare by implementing pricing regulations, insight on 
the current regulations need to be assessed. Hence this research study will avail more 
information and propose recommendations towards future policy advancements. 
Medicine policy regulations are currently utilized within the two-tiered healthcare system. 
Information on the functionality, effectiveness, productivity, and success of the existing 
systems is scarce and is necessary for guiding future developments in SA’s healthcare 
system. One of the future healthcare developments currently being phased in is the NHI. 
With NHI in progress, the medicine pricing procedures that will be undertaken during the 
initiation of such programs remain indefinite. This makes all available data associated with 
medicine pricing regulations in SA particularly important especially with the 
implementation phase of the NHI already on its way. Thus, the lessons gained from this 
study will assist in expanding knowledge on practices of the present regulatory systems and 
4  
recommend improvements that need to be incurred to accommodate the NHI program. 
The value of this study will assist and improve the lack of transparency in medicine prices 
for both healthcare sectors of SA. It has been stated that some public tender medicine prices 
are approximately one-tenth that of the private medicine prices (Makholwa, 2014). This 
study will explore if such comparisons in medicine prices exist and the extent of price 
differences that are encountered. The findings will form a transparent outline of the 
regulations that are in practice by displaying the actual prices of medicines in each sector. 
1.4 Research Methodology 
A two-step research approach was used in this study. This consisted of a literature review 
phase followed by empirical investigations. 
1.4.1 Literature Review 
A multitude of research articles was explored to form the literature review that provides the 
background, context, and significance of this study. These included journal articles, books, 
and papers written in relation to the South African Pharmaceutical Pricing Systems and how 
it functions. The review explores the pricing systems adopted in SA as well as an overview 
of the pricing regulations practiced around the world. Similar studies that acquired data on 
pricing, accessibility, and availability of medicines globally were also viewed. The focus of 
the review provides insight into the two pricing systems being used in South Africa, i.e. 
• The public tender medicine pricing system, 
• The private SEP system. 
1.4.2 Empirical Investigation  
Medicine selection 
The intended comparison study was descriptive, quantitative, and retrospective in nature. The 
study compared the trends that exist between the medicine pricing systems used in SA for the 
past five years (2014-2018). The public tender system and private SEP system were the two 
systems that were investigated during the study. In order to compare the trends in medicine 
prices within each pricing system, a selection of medicines had to be chosen for the study. The 
basket of medicines chosen for this study was based on that of a study conducted by Xiphu 
and Mpanza which used the WHO/HAI methodology (Health Action International, 2019) to 
explore medicine availability, affordability, and prices (Xiphu & Mpanza, 2004). The 
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medicine list used in the Xiphu and Mpanza study consisted of 42 essential medicines (active 
ingredients), however, this list was amended to fit the requirements for this study. From the 
selected 42 medicines, only medicines that appeared on the EML for all five years were chosen 
and formed the final medicine basket (32 medicines) that would be investigated in the study. 
Data Analysis 
The data required for the quantitative analysis was sourced using publicly available websites 
that recorded the medicine prices of the specific medicine list that was used for this study. 
The SEP list for current and archived data was obtained from the “Medicine Price Registry- 
Open Up website” (Open Up, 2019). The public tender medicine price lists were obtained 
from the National Department of Health website where the current and past tender contracts 
were posted, including the addendum for certain contracts (Department of Health, 2019). 
After prices were collected for the selected medicines, Microsoft Excel 2016 analysis tool 
was used to graphically represent the data. The study was further analysed by listing the trends 
that were found, calculating the average price difference, and calculating the average price 
index. 
The results from the study were used to answer the objectives of this research and the 
findings of this thesis were synthesized to form recommendations for the future healthcare 
programs in SA including the NHI. 
1.5 Ethical Approval 
Ethical approval for this study was obtained from the University of KwaZulu-Natal 
Humanities and Social Science Research Ethics Committee (HSS/0421/019M) (see 
Appendix 1). Ethics training was additionally completed by means of the National Institute 
of Health Office of Extramural Research (see Appendix 2). 
1.6 Chapter Summary 
This chapter summarizes the study’s rationale and significance, research questions, aims, 
objectives, and a brief outline of the research methodology. 
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CHAPTER 2: LITERATURE REVIEW 
2.1 Introduction 
South Africa’s healthcare system has a unique setup that is controlled by specific policies 
and regulations. These regulations are instituted in the pharmaceutical sector which is guided 
by protocols to enhance and improve healthcare, particularly targeting expenditure. This 
chapter will focus on introducing the South African healthcare structure together with the 
pharmaceutical pricing regulations that govern this structure. It will provide insight on 
similar study approaches conducted on accessibility and availability of medicines, and 
explore comparable regulatory approaches practiced worldwide. 
2.2 South Africa’s Healthcare System 
2.2.1 The Facts and Figures 
South Africa (SA) is regarded as a middle-income country (The World Bank group, 2020) 
with healthcare governed by a unique two-tiered system (Department of Health, 2003). This 
two-tiered system is divided into the public sector and private sector, with a disproportionate 
distribution of finances and resources. The public sector renders healthcare to 84% of the 
population while 16% is covered by the private sector service (National Department of 
Health, 2015). With approximately 64.7% of the country inhabiting provinces that are 
considered rural (Mahlathi & Dlamini, 2017), the majority of the population access 
healthcare via the public health sector. Low-income residents mainly utilize the public 
healthcare facilities while higher-income residents (some having private medical aid 
insurance) utilize the private health sector facilities (Gilson & McIntyre, 2007). 
The public health sector is funded by the government and 40% of all expenditure on health 
emanates from the National Treasury (National Treasury, 2006). Public health consumes 
around 11% of the government's total budget (allocated largely to the nine provincial 
departments) - which is higher than the 5% Gross Domestic Profit (GDP) recommended by 
the World Health Organization(World Health Organization, 2020). This reflects the major 
burden of disease management and treatment that is dependent on the public sector in SA 
(Jobson, 2015).  
While accessibility and availability are a challenge in the public sector, the private sector is 
challenged with affordability issues. Private healthcare services are funded via out-of-pocket 
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financing or medical aid insurance benefits, or private health insurance (e.g. dreaded disease 
cover) or even a combination. Private healthcare needs are met by either clinic or hospital 
facilities. It can be approximated that the private sector spends around R120.8 billion annually 
to cover 16.2% (8.2 million people) of the population, many of which utilize private medical 
aid insurance (National Treasury, 2011). 
The per capita spending on medicine in the private sector is estimated to be ten times that of 
the public sector (Gray & Matsebula, 2000) which depicts the level of divide amongst the 
healthcare systems governing SA. A key constraint affecting both sectors are the high prices 
of medicine (Ngozwana, 2016). The high prices of medicine which is a key component that 
influences the affordability of healthcare brought about the need for pricing policies and 
regulations. With the unique functioning of a two-tiered medical system coupled with 
financial constraints, the pharmaceutical system of SA faces the same divide in its 
functionality. 
2.3 South Africa’s Pharmaceutical Pricing Systems 
Access to improved healthcare with limited resources is a worldwide challenge. The goal to 
achieve universal health coverage (UHC) to provide one of the basic human rights 
(healthcare), is a global imperative. South Africa shared the same goal, culminating in the 
development of the National Drug Policy (NDP). In 1993, the NDP was drafted and 
presented to the president in 1994 (Department of Health, 1996). This policy was approved 
and published in 1996. Subsequently, the pricing committee was tasked to develop a pricing 
plan for medicines used in SA for the public and private sectors (Gray, et al., 2017). The 
three main domains of the focus of the NDP were; health objectives, economic objectives, 
and national development objectives (Department of Health, 1996). Specifications of the 
economic objectives were to: 
• lower the cost of drugs in both the private and public sectors, 
• promote the cost-effective and rational use of drugs, 
• establish a complementary partnership between government bodies and private providers in 
the pharmaceutical sector, 
• optimize the use of scarce resources through co-operation with international and regional 
agencies. (Department of Health, 1996) 
The specific objectives for the economic domain outlined by the NDP influenced the 
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establishment of medicine pricing policies. With the public and private sector functioning in 
different pharmaceutical and medical structures, the regulations practiced in each sector 
exhibit a similar divide. 
2.3.1 Tender Medicine Pricing System (public sector) 
The public medicine supply is governed by the tender process which is a method aimed at 
attaining price advantages and the standardization of code lists in the public sector (Berger, et 
al., 2010). The medicine procured is in accordance with an essential medicine list (EML) 
guided by the standard treatment guidelines (STG) which is utilized in the public sector for 
the treatment of specific disease conditions. 
Financing and funding of medicines in the public sector are covered by the government. The 
Department of Health’s access to affordable medicines directorate, together with the National 
Treasury (NT), are responsible for the arrangement of national tenders for medicines (Berger, 
et al., 2010). Medical devices are procured through provincial tenders. The tender system is 
defined by the World Health Organization (WHO) as “any formal and competitive 
procurement procedure through which offers are requested, received and evaluated for the 
procurement of goods, works or services, and as a consequence of which an award is made to 
the tenderer whose tender/offer is the most advantageous” (World Health Organization, 1999). 
“Advantageous” in the case of medicines, correlates to factors such as efficacy, cost-
effectiveness, and/or the availability of the medicine being procured. These factors outline the 
important aspects that need to be accounted for when utilizing the tender method, especially 
when concerning medicine choice—which is not a straightforward process. 
The tender system uses a two-stage scoring process to determine who will be awarded the 
tender (Wouters, et al., 2018). The scoring is firstly based on the lowest price (90 points) and 
secondly based on broad-based black economic empowerment scores (10 points) (Wouters, et 
al., 2018). Other factors such as the company performance history may also influence the 
manner in which a tender will be awarded i.e. split tender versus single tender. 
The tender system undergoes many financial difficulties including medicine stock-outs and 
exhaustion of medicine budgets (Berger, et al., 2010). However, some methods are adopted in 
the tender process to assist with these challenges. This involves bidding medicine through a 
split tender system whereby the tender contract is not awarded to a single supplier (Dranitsaris, 
et al., 2017). A split tender approach for the medicine tenders allows for multiple companies to 
supply medicines of the same drug class and can be issued in different pack sizes depending on 
10  
each company. Besides stock-out issues, budget compliance for medicine procurement is 
another challenge endured which is difficult to adhere to but is necessary since funding is 
limited. 
The financing of medicines in SA’s public tender system is conducted via two basic funding 
mechanisms i.e. equitable shares and conditional grants (Berger, et al., 2010). Equitable share 
is a platform that provides each 
sphere of the government with an equitable share of revenue that is raised nationally and 
allocated to each province to perform basic services and functions assigned (Berger, et al., 
2010). Conditional grants are “conditional allocations to provinces and municipalities from 
the national government’s share of revenue raised nationally, which are conditional on certain 
services being delivered or on compliance with specified requirements. Each conditional grant 
has its own specific performance indicators that are reported against and monitored by Treasury 
and the NDOH” (Berger, et al., 2010). HIV/AIDS services are an example of medicines that are 
funded via a conditional grant while most other disease conditions and services (non-
HIV/AIDS conditions) are funded through equitable share funding (Berger, et al., 2010). 
2.3.2 SEP System (private sector) 
The medicine procurement approach in the private sector differs from the methods utilized in 
the public sector. In the past, this system functioned using an unregulated approach. 
Transparent pricing regulations for medicines became necessary (due to many reasons 
including high medicine prices) and was introduced in the early 2000s. Several system reforms 
were executed concerning medicine pricing in the private sector, some of which included the 
banning of sampling (2002); mandatory generic substitution (2003); removal of discounts, 
bonuses, and rebates, and the introduction of the Single Exit Price (SEP) policy (2004) 
(Bodhania, 2007). 
The banning of sampling was a concept dating as far back as 1978 made mention by the Snyman 
Commission (Republic of South Africa, 1962). This statement claimed how “bonusing” and 
reward systems made to healthcare providers should be banned to decrease a biased industry. 
This premise was implemented almost two decades later when the regulation to remove 
discounting, bonuses and rebates were introduced (Gray, 2009). The regulation of banning 
sampling allows for a transparent business arrangement to proceed by permitting no favour, 
discount, or reward from the pharmaceutical company to purchasers (pharmacies and doctors), 
for buying products in increased quantities. Patients benefit from the banning of sampling 
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regulation as the medicines sold to them will not be based on a bias (due to rewarding) but rather 
on the medicine efficacy irrespective of how it was procured. 
 Mandatory generic substitution, another medicine pricing regulation, was implemented and 
introduced in 2003 (Gray, et al., 2016). The regulation is a major cost-saving enterprise for 
patients as it enables them to be offered safe effective medicines at lower costs. This regulation 
stipulates that a pharmacist must offer a generic equivalent, which the patient could accept or 
refuse unless otherwise specified by the doctor or regulated by a non- substitutable list (Gray, 
et al., 2016). Implementation of generic substitution decreases out-of-pocket expenditures and 
medical aid schemes are able to adopt this system to assist patients by creating drug 
formularies based on lower costing generic medicines. The concept of drug formularies is to 
deter patients from acquiring higher costing medicines that are out of the drug formulary as 
opposed to the lower costing generic medicine which would prevent them from incurring co-
payments. However, the success of the generic substitution regulation remains dependent and 
is influenced by patient education on generic medicine (Bangalee, 2015). 
Further to generic substitution, the SEP system was introduced in 2004 (Moodley & Suleman, 
2019). This mechanism stipulates the maximum price (ex-manufacturer price + logistics fee + 
VAT) at which pharmaceutical manufacturers and importers can sell their products as per The 
Medicines and Related Substances Control Act 101 of 1965 as amended (The Republic of 
South Africa, 2002) The SEP prices are regulated by an annual inflation cost that is stipulated 
by the Minister of Health, which is based on the following provisions (Green Gazette, 2017): 
• “The average Consumer Price Index (CPI) for the preceding year 
• The average Purchaser Price Index (PPI) for the preceding year 
• Changes in the rates of foreign exchange and purchasing power parity 
• International pricing information relating to medicines and scheduled substances 
• Comments received from interested persons in terms of regulation 8(2) 
• The need to ensure the availability, affordability, and quality of medicines and scheduled 
substances in the Republic” 
(Green Gazette, 2017). 
The SEP policy regulates the cost of medicines in their different branded forms (e.g. active 
ingredient paracetamol, includes Panado®, Painblok®, and other generic brands that are 
available for the same ingredient). Several brands of medicines are produced by different 
pharmaceutical companies that set different costs for their specific brand of medicine. 
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However, the specific cost that a medicine is agreed upon is not sold at this uniform price 
throughout the pharmaceutical market. Additional to the SEP amount, a dispensing fee can be 
added which makes up the final price a patient will pay for their medicine at a pharmacy. The 
dispensing fee is regulated by stipulating the maximum amount that can be added to the SEP 
as follows: 
a) “where the single exit price of a medicine or scheduled substance is less than one hundred 
and nine rand and fifty-six cents (R109.56), the dispensing fee shall not exceed R14.50 
plus 46% of the single exit price in respect of that medicine or scheduled substance; 
b) where the single exit price of a medicine or scheduled substance is greater than or equal to 
one hundred and nine rands and fifty-seven cents (R109.57), but less than two hundred 
and ninety-two rand and twenty-five cents (R292.25), the dispensing fee shall not 
exceed R27.75 plus 33% of the single exit price in respect of that medicine or scheduled 
substance; 
c) where the single exit price of a medicine or scheduled substance is greater than or equal to 
two hundred and ninety-two rand and twenty-six cents (R292.26), but less than one 
thousand and twenty-two rand and ninety-four cents (R1022.94), the dispensing fee 
shall not exceed R79.00 plus 15% of the Single Exit Price in respect of that medicine or 
scheduled substance; 
d) where the single exit price of a medicine or scheduled substance is greater than or equal to 
one thousand and twenty-two rand and ninety-five cents (R1022.95), the dispensing fee 
shall not exceed R182.00 plus 5% of the Single Exit Price in respect of that medicine or 
scheduled substance.” 
(The Department of Health, 2019) 
The dispensing fee that is added to the SEP is derived by the specific pharmacy (chain store 
pharmacies will stipulate a standard fee across) and is capped accordingly. This explains the 
variation in costs for a particular branded medicine in different pharmacies. The addition of 
the dispensing fee creates a competitive market in the pharmaceutical dispensing industry. 
The logistics fee component, which is inclusive in the SEP, is determined and negotiated 
between manufacturer or importer and the logistics service provider (Green Gazette, 2020). It 
can be set to range from as little as no fee or the alternate, a high valued fee, provided that the 
total price (SEP) stays within the annual SEP percentage increase. The logistics fee process 
still requires further regulation and transparency as these fees have an impact on the final 
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purchasing price of a product. 
The regulations that were implemented in the private sector market were intended to create a 
more transparent pricing system for SA. A transparent pricing system is foreseen to assist 
toward the goal of achieving UHC intended for SA. Similarly, the global pharmaceutical 
market has also implemented different pharmaceutical pricing approaches towards improving 
their healthcare systems. 
2.4 Pharmaceutical Pricing Policies Across the World 
Pharmaceutical pricing protocols follow different practices around the world. Each country 
has adopted specific approaches that work in the best interest of its citizens. The practices 
however differ between most countries, even among first world countries. 
The United States of America (U.S.A) institutes a less regulated pharmaceutical pricing 
environment in comparison to other first world countries. Classified as one of the countries 
that exhibits the highest medicine costs, it also expands the highest research and development 
of newer medicines (Gross, et al., 1994).The USA utilizes an un-regulated approach for 
pricing medicines to promote newer medicine development. It is estimated that when there is 
a decrease in medicine prices due to price regulations, there will be less focus emphasized 
toward early-stage research and development of newer medicines. This makes the implication 
of pricing controls for the U.S.A questionable as new medicine development is at stake (Abott 
& Vernon, 2005). Increased funds are needed to sustain research and development of newer 
medicines; thus, such costs are usually covered within the prices of the medicine (which 
potentially decreases the affordability of the drug). The U.S.A believes that if medicine prices 
were to be regulated, focus toward new research and development would be neglected as the 
costs associated with funding the new developments will be unfeasible and unaffordable. 
The U.S.A health system can be described as a hybrid system as healthcare coverage is not 
uniformly covered (Department for Professional Employees, 2016). Operating within such a 
unique healthcare system creates difficulty for citizens to afford medicines, which is the 
consequence of a market infiltrated by high medicine prices. The out-of-pocket expenditure 
experienced by the U.S.A citizens is increasing, and uninsured patients are a principal factor 
that has led to this situation (Sarnak, et al., 2017). Thus, we find that access and affordability 
of medicines, in a first world country, is also a challenge. 
The United Kingdom (U.K.) functions using a more regulated approach in relation to medicine 
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pricing policies. Regulation in European countries is either guided using a direct or indirect 
approach. The U.K., however, utilizes a more indirect approach known as profit controls 
(Gross, et al., 1994). Profit controls utilize a price ceiling method such that manufacturers 
introducing new medicines into the market can set the selling price of the medicine to any 
amount that does not exceed the negotiated target—which is usually set by the National Health 
Service (NHS) (Gross, et al., 1994). This aids in regulating the prices of medicines when 
reaching the pharmaceutical dispensing market. Unlike the U.S., the U.K. citizens are funded 
for medical care through the NHS which is a UHC system. 
Other European countries such as France, Germany, and Sweden utilize additional 
mechanisms to control medicine prices. This includes methods such as “product-by-product 
price controls” and “limits on insurer reimbursement prices” (Gross, et al., 1994). The product-
by-product price control is a more direct method of controlling prices and involves 
manufacturers setting their medicine prices in accordance with the Government (or the 
responsible paying authority), while new prices and price increases are negotiated via both 
parties (Government and manufacturer). This was typically practiced in Sweden (until 1993) 
and France (Gross, et al., 1994), and such practice mandates that specific criteria be followed 
to establish these prices. The price control executed via limiting the insurer reimbursement 
prices is commonly known as reference pricing. This involves setting limits on prices of 
medicines either based on prices from other countries or comparable to a generic brand 
available in one’s own country. However, the insurer will only cover the cost of the referenced 
medicine price. Any costs incurred exceeding the said referenced price must be covered by the 
consumer (out-of-pocket cost). Such practice encourages that the referenced medicine price be 
used which introduces an opportunity for increased generic drug utilization. Sweden calculates 
its reimbursement price with its target set at 10% more than the least expensive generic 
equivalent while Germany calculates its product medicine price based on an average of the 
prices of that medicine and similar products, i.e. medicine with the same active ingredients, 
therapeutically comparable active ingredients, and therapeutically comparable effects (Gross, 
et al., 1994). 
High-income countries have pricing policies that are more readily available for use in study 
and investigations, however, this is not the case for low - and middle-income countries 
(LMIC). The LMICs constitute nations that are developing, and these countries usually portray 
less regulated pricing policies than high-income countries (de Joncheere, et al., 2003). The 
LMICs usually utilize private funding to afford medicine thus making out-of-pocket payments 
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in these countries quite high (Nguyen, et al., 2015). There are pricing policies that are practiced 
in some LMICs, however, due to lack of documented data, it is difficult to indicate what 
pricing policies work best or what conditions result in policy failures (Bangalee & Suleman, 
2018). However, some of the pricing techniques and pricing policies that have been recorded 
in some LMICs are as follows: 
• External reference pricing: Pakistan (for medicines in the third category: new 
molecules), Taiwan, Vietnam (in regulation only), Bulgaria, Hungary, Turkey 
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• Internal reference pricing: Bulgaria, Hungary, Turkey, Philippines, Thailand (for setting 
up the price ceiling for medicines procured by public hospitals), Taiwan 
• Pharmacoeconomic evaluation for value-based purchasing: Brazil, Bulgaria, Hungary, 
Turkey, Thailand, Taiwan, Philippines 
• Cost plus pricing: India (before 2012), Vietnam, China, Sri Lanka 
• Fixing price at retail/pharmacy level: Maximum Retail Prices (MRP): China, India, 
Philippines, Sri Lanka, South Africa 
• Fixing price at wholesale level: maximum wholesale price: Sri Lanka 
• Fixing price at the ex-manufacturer and importer level: Bulgaria, Hungary, Turkey, Sri 
Lanka, Vietnam 
• Limiting price increases, price freezes: Hungary, India (price freeze in 1963, prior 
approval of the government for price increase from 1966), Taiwan, Vietnam 
• Price cuts: China, Pakistan, Philippines 
• Margin cuts: Hungary 
• Fixed mark-ups: Bangladesh, China (fixed mark-ups between 1980 and 2000 and 
currently zero mark-ups in public health facilities), Sri Lanka 
• Capped mark-ups: India (before 2012) 
• Regressive mark-ups: Vietnam (Public hospital pharmacies only), Bulgaria, Hungary, 
Turkey, South Africa 
• Fixed dispensing fees: South Africa, Sri Lanka 
• Prohibition of discounts: South Africa 
(Nguyen, et al., 2015) 
Efforts to better healthcare systems with medicine pricing regulations are apparent in both 
high-income and LMICs however, there is no global standardized method that can be 
implemented and function for every country. Each nation has to adopt its own objective in 
implementing these regulations bearing in mind the feasibility of such interventions to obtain 
successful outcomes (Bangalee & Suleman, 2018). With medicine costs affecting countries 
globally, access to data and recording of data is particularly important as this assists in making 
decisions on which regulations may work or not. Approaches that provide information on 
accessibility and availability of medicine is an important tool that is used to assist policymakers 
when creating pharmaceutical pricing regulations and is a global initiative adopted to provide 
a platform where this data can be accessed. 
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2.5 South Africa in the Health Action International (HAI) Project 
Health Action International (HAI) together with the World Health Organization (WHO) 
developed a project on medicine prices and availability targeting the following objectives: 
• “To develop a reliable methodology for collecting and analyzing medicine price, 
availability, affordability, and medicine price component data across health-care sectors 
and regions in a country 
• To publish survey data on a publicly accessible web site to improve price transparency 
• To advocate for appropriate national policies and monitor their impact” (WHO & HAI, 
2008). 
With these goals set out for the project, the development was able to create a tool that is 
accessible and useful to countries around the world. Several countries participated in this 
project, including SA. The survey component involved gaining information to generate 
reliable data on the price, availability, and affordability of selected important medicines and 
price components in the supply chain (WHO & HAI, 2008). The selection of the medicines to 
be surveyed comprised up to 50 medicines including: 
1. “A global core list of 14 medicines that are included in all medicine price surveys to enable 
international comparisons. 
2. A regional core list of 16 medicines that accounts for regional differences in medicine 
usage but still allows for comparisons across countries within the same region (which was 
later removed). 
3. A supplementary list of at least 20 medicines, selected at the country level for their local 
importance” (WHO & HAI, 2008). 
SA participated in the study and executed the survey in the Gauteng region in 2004 (Xiphu & 
Mpanza, 2004). The medicine selection consisted of 42 medicines: 28 from the core list and 
14 from the supplementary list (Xiphu & Mpanza, 2004). Of the 42 medicines selected, 39 
were part of the EML (Xiphu & Mpanza, 2004). The EML is a main component that is utilized 
in the public sector and the survey was facilitated in both private and public sector, hence the 
choice of selecting medicines from the EML during the survey was vital. 
Table 1: Medicine list used during the HAI survey conducted in the Gauteng region 
(Health Action International, 2019) 
ACTIVE 
INGREDIENTS 
DOSAGE FORM ACTIVE INGREDIENTS DOSAGE FORM 
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1. Aciclovir 200 mg cap/tab 22. Ibuprofen 400 mg cap/tab 
2. Allopurinol 300 mg cap/tab 23. Indinavir 400 mg cap/tab 
3. Amitriptyline 25 mg cap/tab 24. Lamivudine 150 mg cap/tab 
4. Amoxicillin 250 mg cap/tab 25. Loperamide 2 mg cap/tab 
5. Atenolol 50 mg cap/tab 26. Losartan 50 mg cap/tab 
6. Beclometasone 50 mcg/dose inhaler 27. Metformin 500 mg cap/tab 
7. Captopril 25 mg cap/tab 28. Methylphenidate 10 mg cap/tab 
8. Carbamazepine 200 mg cap/tab 29. Metoclopramide 10 mg cap/tab 
9. Ceftriaxone 1 g/vial injection 30. Nevirapine 200 mg cap/tab 
10. Ciprofloxacin 500 mg cap/tab 31. Nifedipine 10 mg cap/tab 
11. Co-amoxiclav 250+125 mg cap/tab 32. Nifedipine 20 mg tab Retard 
12. Co-trimoxazole 40+200mg/5ml suspension 33. Omeprazole 20 mg cap/tab 
13. Diazepam 5 mg cap/tab 34. Phenytoin 100 mg cap/tab 
14. Diclofenac 25 mg cap/tab 35. Prednisone 5 mg cap/tab 
15. Efavirenz 600 mg cap/tab 36. Promethazine 25 mg cap/tab 
16. Fluconazole 150 mg cap/tab 37. Ranitidine 150 mg cap/tab 
17. Fluconazole 200 mg cap/tab 38. Salbutamol 100 mcg/dose inhaler 
18. Fluoxetine 20 mg cap/tab 39. Stavudine 30 mg cap/tab 
19. Fluphenazine 25 mg/ml injection 40. Stavudine 40 mg cap/tab 
20. Glibenclamide 5 mg cap/tab 41. Sulfadoxine + 
Pyrimethamine 
500+25 mg cap/tab 
21. Hydrochlorothiazide 25 mg cap/tab 42. Zidovudine 100 mg cap/tab 
 
The HAI project facilitated in SA was able to contribute to the global objective of UHC. The 
availing of information on medicine prices and availability in SA was able to provide data that 
assisted with medicine policy development. With the initiation of the NHI program in SA, such 
tools are imperative for guiding future projections in SA. Similar practices used in this survey 
such as the EML component may be executed during the NHI program, which makes price 
comparisons of medicines quite significant. However, an outlook of universal health in 
countries around the world is also an important component that can guide decisions that will 
influence NHI in SA. 
2.6 Universal Health Coverage (UHC) Across the Globe 
UHC is established to assist in the worldwide struggle of cost containment in healthcare. The 
UHC system encompasses medical insurance coverage for all people in a nation which is 
administered via the public sector, private sector, or a combination of both. 
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Several first world countries have established UHC executing numerous mechanisms to 
achieve this. “Universal health coverage” can be classified as a broad term and can be 
accomplished through different methods thus having different meanings in each country 
depending on their approach towards this goal (Giovanella, et al., 2018). Some of the 
approaches include; predominantly public insurance, regulated private insurance, and mixed 
public-private insurance (Seervai, et al., 2017). 
Predominantly public insurance is practiced in the U.K. via the single-payer model. This model 
is funded via the government through taxes and pays the providers directly, covering all 
residents for complete healthcare with no co-payments (Seervai, et al., 2017). The Netherlands 
practices the regulated private insurance mechanism. This method functions by citizens paying 
a premium towards a private insurance who subsidizes the payment to the healthcare provider. 
All citizens are required to join this program (exceptions are granted to some citizens who 
qualify) and this service covers government-defined health benefits with deductibles for some 
services (Seervai, et al., 2017). France practices the mixed public-private insurance system, 
where all residents are covered by governmental non-profit funds that pay providers. 
Additionally, private insurance can be bought to cover the gaps not funded by the government 
(Seervai, et al., 2017). 
The NHI model is another mechanism aimed to achieve UHC and is practiced in Canada. This 
model, also known as Medicaid, uses private healthcare providers but are subsidized from a 
governmental insurance program (which citizens contribute towards either through premiums 
or tax) (Wallace, 2013). The benefits of the program provide cover to all citizens independent 
on their earnings, age, or province of residence (Martin, et al., 2018). Although residents are 
subsidized for healthcare needs, not all prescription drug coverage is met. 
There is no national standard for drug coverage in Canada. Each province permits its own 
coverage of medicine costs. One of the greatest differences in the methods executed in each 
province is the medicine benefits that are available to the residents that are not on social 
assistance, or who are 65 years or older (Brandt, et al., 2018). Premium-based medicine 
coverage which is sometimes subjected to monthly premiums and co- insurance on 
prescriptions filled are offered in some provinces such as Alberta, New Brunswick, and 
Quebec (Brandt, et al., 2018). Some provinces offer private insurance which is mandatory to 
citizens that qualify for extended health benefits and is available in other provinces on a 
voluntary basis. 
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High out-of-pocket costs are still experienced in Canada, even in a combined private and 
public health coverage approach (Brandt, et al., 2018). Methodologies such as generic 
substitution and, generic or therapeutic reference-based compensation are practiced in some 
of the provinces to control the expenditure of medicines in their provinces (Canadian Health 
Services Research Foundation, 2005). One of the recommendations towards universal drug 
coverage for Canada is the compilation of a National Drug Formulary which is similar to the 
EML used in SA. The formulary is recommended to be funded using the single-payer public 
program and the recommendations were made towards forming universal pharmacare for 
Canada (Brandt, et al., 2018). 
The aim of UHC is not an easily achievable goal as seen in countries that practice this 
approach. It is advantageous for SA to review the practices of other countries as strengths 
and weaknesses can be observed. With Canada already practicing the NHI approach, it is 
important for SA to note the successful components of such a system. 
2.7 The Projected NHI Programme for South Africa 
The progression towards NHI in SA is intended to be accomplished by 2030. The NHI program 
has been a work-in-progress involving several stages of execution and is nearing the stage of 
complete implementation. 
The NHI program is intended to lower the financial burdens of healthcare experienced by 
South African citizens. The project aims to provide an equitable health service to all, regardless 
of their socioeconomic status. It will require a massive re-organization of the public and private 
health sectors to accommodate this change. The NHI program intends to provide a single fund 
that is administered and owned publicly. It stems from forming a culture of values that 
embraces justice, fairness, and social solidarity (Government of South Africa, 2020). 
The increased expenditure experienced in SA’s private sector has been difficult to reduce. 
There are tools currently in place to decrease the financial burden; however, high costs of 
healthcare still exist. This forms the foundation and purpose of introducing the NHI. The 
system is proposed to form coverage for hospital, pharmaceutical, laboratory, and radiology 
services. These services will be subsidized by the NHI which aims to pool the revenue for this 
fund via tax contributions by the citizens. The tax revenue that is collected will be apportioned 
towards funding this program and both the employed and unemployed will be covered from 
the public pool of funds (Government of South Africa, 2020). 
The pharmaceutical sector will function utilizing a medicinal formulary (similar to the EML) 
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that should be adhered to. If treatment remains within the boundaries of the medicine 
formulary, complete subsidizing and funding will be awarded. If an individual chooses 
treatment outside of the formulary boundary, the treatment will be covered by the individual 
or their private medical aid insurance. Private medical aid insurance will still be available to 
those who can afford it, however, contributions towards the NHI fund will be mandatory. 
Although contributions will not be optional, the choice of utilizing the program will be. 
According to the proposed NHI system, medicines will be accessible at both public and private 
healthcare facilities. These facilities will procure the specified medicines that are on the 
formulary and will be subsidized by the public fund for the purchases made. There is no 
stipulation on the procurement system that will be adopted for obtaining medicines in this 
program. The tender system, SEP system, or perhaps a combination of both may be the 
approach taken, however, with the program still in the pilot phase, decisions are still underway 
(Government of South Africa, 2020). 
With the NHI in its pilot phase, the decisions that influence how it will function need to be 
decided before the program is fully enforced. Further studies that can aid the NHI program 
will assist policymakers during the implementation phase of the program and is necessary. 
2.8 Chapter Summary 
South Africa’s goal towards universal health coverage is much anticipated. As noted from 
practices around the world, pharmaceutical pricing regulations as well as universal health 
coverage systems are complex yet unique. Though different systems are practiced, the 
objective of the systems shares the same goal — decreasing the financial burden of healthcare. 
The studies appraised are significant as South Africa moves towards UHC and requires that the 
strongest components of all policies be amalgamated in order to ensure sustainable access to 
quality and affordable essential medicines. 
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CHAPTER 3: MANUSCRIPT FOR SUBMISSION AND PUBLICATION 
3.1 Introduction 
This chapter describes the general findings and discussion of the results of the study and is 
presented in the form of a manuscript entitled “A comparison study between public and private 
healthcare sector medicine prices in South Africa”. The manuscript was submitted to the 
Journal of Pharmaceutical Health Research Services and was formatted accordingly (see 
Annexure 3). 
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Abstract 
 
Objectives 
The objectives of the study were to compare price trends, determine price differentials, 
and equate the average price index of a basket of medicines between the public and 
private healthcare sectors in South Africa. 
   
Methods 
A price list consisting of 32 essential medicines available in both the public and private 
healthcare systems of South Africa was chosen for this study. The price of medicines 
for the private sector were obtained from the Medicine Price Registry- Open Up 
website for the period 2014-2018. Public sector medicine prices were obtained from 
the Department of Health website for the corresponding period. Observations and price 
trends were identified and analyzed using Microsoft Excel version 2016. 
 
Key Findings 
A total of 74 medicine brands were analyzed in the study. It was found that the prices 
across both sectors had increased over time, however, the majority of brands (87%) 
displayed higher prices in the private sector in comparison to the public sector. On 
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average, the price differential between the private and public sector medicines were 
395.47%.  
Conclusion 
The study found varying price differences between medicines in the public and private 
sectors because of the different methodologies used in each. The reasons for changes 
in medicine prices across the years in both sectors, could not always be clearly 
determined as both sectors lacked complete transparency in the processes applied to 
establish medicine prices. Therefore, more transparent medicine price systems need 
to be considered for the future of South Africa’s healthcare system as the country 
transitions toward universal health coverage. 
Keywords 
• Public tender prices 
• Single exit price (SEP) 
• Medicine price trends 
• South Africa  
 
 
 
Introduction 
The regulation of medicine prices is a complex economic process. Globally there have 
been several policies and regulatory interventions that have been implemented to 
improve medicine price (Volger, et al., 2017). In South Africa (SA), previous health 
system disparities, and increasing medicinal costs warranted the need for better 
medicine price systems  (Moodley & Suleman, 2019).  Efforts to achieve this included 
the development of the  National Drug Policy (NDP), which laid the foundation for 
medicine price strategies in both the public and private healthcare sectors (Department 
of Health, 1996). 
The South African healthcare system is divided into two sectors which have different 
funding sources i.e. the public sector (government funding) and the private sector 
(private medical aid insurances and out-of-pocket funding). The public and private 
sectors warrant different pharmaceutical price regulations as the fundamental 
practises in each sector are different and are therefore regulated accordingly (e.g. the 
different funding methods for each).Additionally medicine and healthcare resource 
distribution is also unbalanced across the both sectors. The accessibility and 
availability of healthcare in this polarised system, therefore, provides unequal health 
benefits to patients being treated in each sector (Burger & Christian, 2020).  
Measures to regulate medicine prices in the private sector required the construction of 
greater transparency in the South African pharmaceutical price system. In the past, 
drug prices in SA had inflated artificially through bonuses, discounts, rebates, and 
other incentives schemes that led to the dispensing of more expensive drugs 
(Ngozwana, 2016). This led to the introduction of several regulatory mechanisms to 
improve transparency which included the banning of sampling; mandatory offering of 
generic substitution; removal of discounts, bonuses and rebates; and among these, 
the introduction of the single exit price (SEP) intervention (Bodhania, 2007).  
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The SEP can be defined as a mechanism that regulates the maximum price at which 
a medication can be charged (Open Up, 2019). All medicines in the private sector are 
governed by the SEP regulation with two exceptions, this being, veterinary medicines 
and over-the-counter schedule zero medicines (Moodley & Suleman, 2019). The SEP 
undergoes an annual regulated maximum increase which is set by the Minister of 
Health. This increase is based on several provisions which include the average 
consumer price index (CPI) and the average producer price index (PPI) for the 
preceding year (Green Gazette, 2017). The final SEP of a medicine is made up of 
three components i.e. the ex-manufacturer price (set by the manufacturer), logistics 
fee (set by the manufacturer); and value-added-tax (14%). 
 
In the public sector, medicine prices are regulated by a tender system which is also 
available as an exit price. The pharmaceutical tenders are advertised on a public forum 
where several pharmaceutical companies bid on the tender (Wouters, et al., 2018). 
The medicine quantity and the type of medicine required for each tender depend on 
the need of each province and the overall process is monitored by the National 
Department of Health (NDoH) (Wouters, et al., 2018). The Government purchases the 
medicine at the specific price stipulated by the pharmaceutical company that was 
awarded the tender (Wouters, et al., 2018). This price is exclusive only to the 
government (for the tender) and is not available in the private sector. In some 
instances, the same tender can be awarded to multiple pharmaceutical companies to 
prevent medicine shortages (Dranitsaris, et al., 2017). This tender system has been in 
use in the public sector for several years with not many variations to the systems 
applied. 
Medicines procured in the public sector are based on an Essential Medicine List (EML). 
The EML contains a list of the safest and most effective medicines that satisfy the 
priority health needs of a country (WHO, 2020). The essential medicine list contains 
the list of medicines in its active ingredient form. Globally, issues concerning essential 
medicine access led to the development of the World Health Organization 
(WHO)/Health Action International (HAI) methodology, which aimed to publish a 
country’s survey data on a publicly accessible website. This project intended to 
improve medicine price transparency (WHO & HAI, 2008). The methodology was 
applied by Xiphu and Mpanza in SA and resulted in the following findings relating to 
medicine prices: there was a lack of transparency and uniformity of mark-ups by 
retailers and; most facilities did not adhere to medicine price regulations and had high 
medicine prices in comparison to international reference price (Xiphu & Mpanza, 
2004). 
The global market has also made several attempts to regulate medicine prices. In 
several low and middle- income countries, such as Brazil and Argentina, pricing 
policies were introduced to reduce medicine prices. It was found however, that despite 
an initial decrease in prices, these reductions were not sustainable, eventually leading 
to prices increasing over time (Kohler, et al., 2015) (Schargrodsky, et al., 2001). 
Similarly, a study conducted in Spain to anyalze the interventions implemented to 
control pharmaceutical expenditure revealed that 12 out of 16 interventions did not 
effectively decrease medicine prices in the short term and the remaining 4 
interventions did not have a sustainable effect thus only resulting in moderate annual 
savings (Moreno-Torres, et al., 2011). Therefore, there is a need to employ 
transparency measures that will ensure sustainability of reduced medicine prices.  
Achieving price transparency is the aim of medicine price regulations in SA, hence the 
progress of these interventions needs to be monitored. Since the introduction of the 
SEP in SA, there have been some studies that looked at the effect and outcomes of 
this price mechanism (Pretorius, 2011) (Moodley & Suleman, 2019). A study on the 
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impact of the  SEP established that since the introduction of the SEP there was a 22% 
decrease in the average prices of medicines (Pretorius, 2011). Another recent study 
evaluated the impact of the SEP policy on a series of originator medicine products and 
determined that the SEP impacted medicine prices both short term and long term 
(Moodley & Suleman, 2019). Tender medicine systems were evaluated in other 
countries such as the Netherlands and China, where it was found to reduce medicine 
prices, however these findings cannot be generalized to all other countries due to the 
several differences in regulatory practise as well as political economies of each 
healthcare system (Barber, et al., 2013) (Kanavos, et al., 2009) (Wouters, et al., 2018). 
The studies conducted in SA focused on the progress of the SEP system however the 
comparison of both price systems was not extensively investigated. 
As SA transitions towards universal health coverage via the National Health Insurance 
(NHI), medicine price mechanisms between the two healthcare sectors need to be re-
evaluated and reviewed to improve systems for future use. Therefore, the objectives 
of this study were to compare price trends, determine price differences, and equate 
the average price index of medicines between the public and private healthcare 
sectors in SA. 
Research Methods 
Study design  
The study was descriptive, quantitative, and retrospective in nature. It was a 
comparison between tender and SEP medicine prices in both the public and private 
health sectors of South Africa for a 5-year period i.e. between 2014-2018. 
Definitions 
For the purpose of the study, 
Branded medicines were defined as “medicines which have a name given to them 
by a company for the purpose of advertising. The names of branded medicines are 
different from the International Non-proprietary Name (INN). Branded medicines may 
be the original medicine developed by a company, or several companies may make 
the same medicine in the generic form to which each company will give its own brand 
name ” (EUPATI, 2015). 
Active ingredients were defined as  “any component of a drug product intended to 
furnish pharmacological activity or other direct effects in the diagnosis, cure, mitigation, 
treatment, or prevention of disease, or to affect the structure or any function of the 
body of humans or other animals. Active ingredients include those components of the 
product that may undergo chemical change during the manufacture of the drug product 
and be present in the drug product in a modified form intended to furnish the specified 
activity or effect” (U.S. FDA, 2020). 
Selection of medicines 
The basket of medicines chosen was based on that of a  study conducted by Xiphu 
and Mpanza which used the WHO/HAI methodology to explore medicine availability, 
affordability, and prices (Xiphu & Mpanza, 2004).  The medicine list in the Xiphu and 
Mpanza study were based on a core list and supplementary list as per the standards 
specified in the WHO/HAI methodology (WHO & HAI, 2008). The core list was 
developed to facilitate international comparisons and could be adjusted to suit each 
countries pattern of medicine use (Xiphu & Mpanza, 2004). The supplementary list 
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allowed for each country to add more medicines that were relevant to it but did not 
appear in the core list. In SA the Pharmaceutical Economic Evaluation directorate at 
the National Department of Health, created a supplementary list of 14 medicines that 
was based on the most sold medicines by volume in the private sector and the 
occurrence of the medicine in the EML (Xiphu & Mpanza, 2004). The medicine list 
used in the Xiphu and Mpanza study therefore consisted of 42 medicines (28 from the 
core list and 14 from the supplementary list), however, this list was amended in line 
with the following inclusion criteria for this study: 
1. For an active ingredient to be included in the final medicine basket, it had to appear 
on the tender medicine list for all five years (2014-2018) chosen for the study. The 
following active ingredients were therefore omitted i.e. fluconazole 150mg cap/tab, 
fluphenazine 25mg/ml injection, ibuprofen 400mg cap/tab, indinavir 400mg cap/tab, 
nifedipine 20mg tab retard, omeprazole 20mg cap/tab, ranitidine 150mg cap/tab, 
stavudine 40mg cap/tab, sulfadoxine+pyrimethamine 500+25mg cap/tab.  
2. Single exit prices were compared to the corresponding branded medicines that 
appeared on the tender list. Therefore, the active ingredient fluconazole 200mg 
cap/tab was excluded because it did not appear on both lists. 
Table 1 presents the final basket of 32 active ingredients that were investigated. 
 
Table 1: Basket of active ingredients (in each category) 
 
Active ingredients 
 Anti-infective medicines (i.e., antibiotic, antifungal, antiprotozoal, and antiviral 
agents) 
1
6 
fluoxetine 20mg cap/tab 
1 acyclovir 200mg cap/tab 1
7 
glibenclamide 5mg cap/tab 
2 amoxicillin 250mg cap/tab 1
8 
hydrochlorothiazide 25mg cap/tab 
3 ceftriaxone 1g/vial injection 1
9 
loperamide 2mg cap/tab 
4 ciprofloxacin 500mg cap/tab 2
0 
losartan 50mg cap/tab 
5 co-amoxiclav 250+125mg cap/tab 2
1 
metformin 500mg cap/tab 
6 co-trimoxazole 40+200mg/5ml suspension 2
2 
methylphenidate 10mg cap/tab 
 Drops, aerosols, inhalers, and inhalants 2
3 
metoclopramide 10mg cap/tab 
7 beclomethasone 50mcg/dose inhaler 2
4 
nifedipine 10mg cap/tab 
8 salbutamol 100mcg/dose inhaler 2
5 
phenytoin 100mg cap/tab 
 Solid-dose medicines and transdermal patches 2
6 
prednisone 5mg cap/tab 
9 allopurinol 300mg cap/tab 2
7 
promethazine 25mg cap/tab 
1
0 
amitriptyline 25mg cap/tab  Antiretroviral medicines 
1
1 
atenolol 50mg cap/tab 2
8 
efavirenz 600mg cap/tab 
1
2 
captopril 25mg cap/tab 2
9 
lamivudine 150mg cap/tab 
1
3 
carbamazepine 200mg cap/tab 3
0 
nevirapine 200mg cap/tab 
1
4 
diazepam 5mg cap/tab 3
1 
stavudine 30mg cap/tab 
1
5 
diclofenac 25mg cap/tab 3
2 
zidovudine 100mg cap/tab 
    
 [The table contains 32 active ingredients divided into four categories according to type 
and/or to the dosage form of the medicine. The first category (numbers 1-6) represent 
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antiinfectives. The second category (numbers 7-8) represents drops, aerosols, 
inhalers, and inhalants. The third category (numbers 9-27) represent solid-dose 
medicines and transdermal patches. The fourth category represents antiretrovirals 
(28-32).] 
 
Medicine price data analysis 
The tender medicine prices were sourced from the Department of Health website 
(Department of Health, 2019), whereas the SEPs for the private sector were obtained 
from the “Medicine Price Registry- Open Up website”  (Open Up, 2019).  All medicine 
prices used in the study were in South African Rands (ZAR). Due to the differences in 
pack sizes between the tender price system and the SEP system, the price per 
standard unit (i.e. per tablet or capsule) was computed.  
All data were analyzed using Microsoft Excel version 2016. The tender medicine prices 
and SEPs were compared to identify the trends that exist between each price system. 
Comparisons were made using the following calculations: 
 
1. The average price difference between the branded medicine prices of the tender and 
SEP systems was determined over the five-year period. The calculation was based on 
the following criteria: 
• Medicine prices compared were calculated and represented as per standard unit pack 
size.  
• The price difference was calculated by expressing the difference between the SEP 
and tender price as a percentage of the tender price for each year in the five-year 
period: 
𝜀𝑖,𝑏 =
𝑆𝐸𝑃𝑖,𝑏 −𝑇𝑃𝑖,𝑏
𝑇𝑃𝑖,𝑏
× 100%       (1) 
𝑤ℎ𝑒𝑟𝑒:  𝜀 𝑖𝑠 𝑡ℎ𝑒 𝑝𝑟𝑖𝑐𝑒 𝑑𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒 
𝑆𝐸𝑃 𝑖𝑠 𝑡ℎ𝑒 𝑠𝑖𝑛𝑔𝑙𝑒 𝑒𝑥𝑖𝑡 𝑝𝑟𝑖𝑐𝑒   
𝑇𝑃 𝑖𝑠 𝑡ℎ𝑒 𝑡𝑒𝑛𝑑𝑒𝑟 𝑝𝑟𝑖𝑐𝑒 
𝑖 𝑖𝑠 𝑡ℎ𝑒 𝑦𝑒𝑎𝑟 𝑖𝑛 𝑤ℎ𝑖𝑐ℎ 𝑡ℎ𝑒 𝑝𝑟𝑖𝑐𝑒 𝑤𝑎𝑠 𝑖𝑛 𝑒𝑓𝑓𝑒𝑐𝑡 
𝑏 𝑟𝑒𝑝𝑟𝑒𝑠𝑒𝑛𝑡𝑠 𝑡ℎ𝑒  𝑏𝑟𝑎𝑛𝑑𝑒𝑑 𝑚𝑒𝑑𝑖𝑐𝑖𝑛𝑒 𝑎𝑡 𝑎 𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝑝𝑎𝑐𝑘 𝑠𝑖𝑧𝑒 
 
• The price difference calculation was applied for each medicine for the corresponding 
year in the five-year period. The calculated percentage per year (𝜀𝑖,𝑏) was used to 
calculate the average price difference: 
𝜀?̅? =
∑ 𝜀𝑖,𝑏
2018
𝑖=2014
𝑛
      (2) 
𝑤ℎ𝑒𝑟𝑒:   𝜀 ̅𝑖𝑠 𝑡ℎ𝑒 𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑝𝑟𝑖𝑐𝑒 𝑑𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒 
𝑛 𝑟𝑒𝑝𝑟𝑒𝑠𝑒𝑛𝑡𝑠 𝑡ℎ𝑒 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑦𝑒𝑎𝑟𝑠 𝑤𝑖𝑡ℎ 𝑎𝑣𝑎𝑖𝑙𝑎𝑏𝑙𝑒 𝑝𝑟𝑖𝑐𝑒 𝑑𝑎𝑡𝑎 
 
2. The average price index was calculated using the following criteria: 
• The average annual price increase was calculated for each branded medicine within 
its pack size over the five-year period. Only branded medicines that had a price value 
for two or more years could be used. The difference between the earliest and the latest 
annual price available for a medicine was used to determine the average price index: 
33  
𝐴𝑃𝐼 =
𝑃𝑦𝑙 − 𝑃𝑦𝑒
𝑦𝑙 − 𝑦𝑒
 × 100% 
𝑤ℎ𝑒𝑟𝑒: 𝐴𝑃𝐼 𝑖𝑠 𝑡ℎ𝑒 𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑃𝑟𝑖𝑐𝑒 𝐼𝑛𝑑𝑒𝑥 
𝑃 𝑟𝑒𝑝𝑟𝑒𝑠𝑒𝑛𝑡𝑠 𝑡ℎ𝑒 𝑝𝑟𝑖𝑐𝑒 𝑜𝑓 a 𝑚𝑒𝑑𝑖𝑐𝑖𝑛𝑒 𝑖𝑛 𝑎 𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝑦𝑒𝑎𝑟 
𝑦𝑙  𝑟𝑒𝑝𝑟𝑒𝑠𝑒𝑛𝑡𝑠 𝑡ℎ𝑒 𝑙𝑎𝑡𝑒𝑠𝑡 𝑦𝑒𝑎𝑟 
𝑦𝑒 𝑟𝑒𝑝𝑟𝑒𝑠𝑒𝑛𝑡𝑠 𝑡ℎ𝑒 𝑒𝑎𝑟𝑙𝑖𝑒𝑠𝑡 𝑦𝑒𝑎𝑟 
 
Ethical Considerations 
Ethical approval for this study was obtained from the relevant University Institution 
(HSS/0421/019M) under the exempt approval as the nature of the study involved 
data/materials available to the public domain.  
Results 
The findings relate to the prices of the final basket of 32 active ingredients that yielded 
a total of 74 branded medicines.   
The tender medicine price and SEP’s for each medicine brand were tabulated (see 
Error! Reference source not found., Error! Reference source not found., and 
REF _Ref42443940 \h  \* MERGEFORMAT Error! Reference source not found.) 
and then graphed for comparisons. 
 
Table 2: Tender medicine prices (per dosage form e.g. Tablet/capsule/suspension) 
from 2014 to 2018 for the basket of 32 medicine active ingredients. 
 
 
Branded Medicine Name Active Ingredient 2014 
Price 
2015 
Price 
2016 
Price 
2017 
Price 
2018 
Price 
Acitab_200_DT 200mg Tablets 25 
Lovire 200mg Tablets 25 
Aciclovir - R 0.40 R 0.48 - - 
R 0.40 - - R 0.41 R 0.41 
Adco-Allopurinol 300mg Tablets 28 
Adco-Allopurinol 300mg Tablets 30 
Puricos 300mg Tablets 28 
Allopurinol R 0.39 - - - - 
- R 0.40 R 0.47 R 0.44 R 0.42 
R 0.43 R 0.44 - - - 
Gulf_Amitriptyline 25mg Tablets 100 
Gulf_Amitriptyline 25mg Tablets 168 
Gulf_Amitriptyline 25mg Tablets 500 
Sandoz_Amitriptyline_HCL 25mg Tablets 28 
Trepiline 25mg Tablets 100 
Trepiline 25mg Tablets 28 
Trepiline 25mg Tablets 56 
Trepiline 25mg Tablets 84 
Amitriptyline - - R 0.15 R 0.14 R 0.13 
- R 0.12 R 0.13 R 0.13 R 0.12 
- - R 0.10 R 0.09 R 0.09 
R 0.09 R 0.09 - - - 
R 0.13 R 0.13 - - - 
- - R 0.16 R 0.15 R 0.15 
R 0.13 R 0.13 R 0.13 R 0.13 R 0.13 
R 0.10 R 0.10 R 0.13 R 0.13 R 0.13 
Allmox 250mg Capsules 100 
Allmox 250mg Capsules 15 
Amoxicillin - - - R 0.29 R 0.29 
- - - R 0.32 - 
Amoxicap 250mg Capsules 15 
Amyn 250mg Capsules 100 
Amyn 250mg Capsules 15 
Austell_Amoxicillin 250mg Capsules 15 
Indo_Amoxycillin 250mg Capsules 15 
Moxymax 250mg Capsules 15 
 - R 0.31 R 0.39 - - 
R 0.22 - - - - 
R 0.23 - - - - 
- - - R 0.37 R 0.37 
- - - R 0.32 - 
R 0.23 R 0.28 R 0.35 - - 
Austell_Atenolol 50mg Tablets 28 
Austell_Tenopress 50mg Tablets 28 
Bio-Atenolol 50mg Tablets 28 
Bio-Atenolol 50mg Tablets 30 
Atenolol R 0.08 - - - - 
- R 0.09 - - - 
R 0.07 R 0.07 - - - 
- - R 0.09 R 0.08 R 0.08 
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Zetenol 50mg Tablets 28 - - R 0.10 R 0.10 R 0.09 
Beceze 50mcg Inhaler 200 
Beclate 50mcg Inhaler 200 
Beclometasone R 0.13 R 0.13 - - - 
- - R 0.16 R 0.13 R 0.13 
Bio-Captopril 25mg Tablets 60 Captopril R 0.11 R 0.11 R 0.17 R 0.16 R 0.15 
Degranol 200mg Tablets 100 
Degranol 200mg Tablets 28 
Degranol 200mg Tablets 56 
Degranol 200mg Tablets 84 
Gulf_Carbamazepine 200mg Tablets 100 
Gulf_Carbamazepine 200mg Tablets 28 
Gulf_Carbamazepine 200mg Tablets 84 
Carbamazepine - - R 0.36 R 0.35 R 0.34 
R 0.26 R 0.27 R 0.46 R 0.45 R 0.45 
R 0.22 R 0.23 R 0.34 R 0.33 R 0.32 
R 0.21 R 0.23 R 0.32 R 0.31 R 0.30 
R 0.24 R 0.26 - - - 
R 0.24 R 0.26 - - - 
- - - R 0.28 R 0.26 
Austell_Ceftriaxone 1g Vial 1 
Fraxone 1g Vial 1 
Kocef-1000 1g Vial 1 
Rociject 1g Vial 1 
Rociject 1g Vial 10 
Ceftriaxone - R 5.69 R 7.18 - - 
- - - R 5.86 R 5.86 
R 4.50 R 5.21 R 6.50 R 6.01 R 6.01 
R 4.57 - - - - 
- - - R 0.61 R 0.61 
Biotech_Ciprofloxacin 500mg Tablets 10 
Cifran 500mg Tablets 10 
Profloxin 500mg Tablets 10 
Ciprofloxacin R 0.48 R 0.56 R 0.68 - - 
- - - R 0.48 R 0.48 
R 0.61 R 0.56 R 0.69 R 0.61 R 0.61 
Auro_Amoxiclav 375mg Capsules 100 
Auro_Amoxiclav 375mg Capsules 15 
Austell_Co-Amoxiclav 375mg Tablets 15 
Sandoz_Co-amoxyclav 375mg Tablets 15 
Co-amoxiclav R 1.05 - - - - 
R 1.12 - - - - 
- - - R 1.90 R 1.90 
R 1.00 R 1.39 R 1.68 R 1.58 R 1.58 
Doctrim 240mg/5ml Suspension 100 
Doctrim 240mg/5ml Suspension 50 
Ilvitrim_Suspension 240mg/5ml Suspension 100 
Ilvitrim_Suspension 240mg/5ml Suspension 50 
Resmed_Cotrimoxazole 240mg/5ml Suspension 100 
Resmed_Cotrimoxazole 240mg/5ml Suspension 50 
Co-trimoxazole R 0.04 R 0.05 R 0.06 - - 
- R 0.06 R 0.07 R 0.07 R 0.07 
R 0.04 R 0.04 R 0.05 R 0.06 R 0.06 
R 0.05 R 0.06 R 0.07 - - 
R 0.04 - - - - 
R 0.05 - - - - 
Betapam 5mg Tablets 100 
Valium 5mg Tablets 100 
Diazepam R 0.09 R 0.09 - - - 
- - R 0.57 R 0.57 R 0.58 
Biotech_Diclofenac 25mg Tablets 15 
Mylan_Diclofenac 25mg Tablets 500 
Mylan_Diclofenac 25mg Tablets 56 
Diclofenac R 0.12 R 0.12 - - - 
- - R 0.08 - R 0.07 
- - - R 0.71 - 
Adco-Efavirenz 600mg Tablets 128 
Adco-Efavirenz 600mg Tablets 28 
Cipla_Efavirenz 600mg Tablets 28 
Cipla_Efavirenz 600mg Tablets 30 
Efavirenz_Winthrop 600mg Tablets 28 
Efrin 600mg Tablets 28 
Sonke_Efavirenz 600mg Tablets 28 
Efavirenz R 0.26 - - - - 
- R 1.56 R 1.75 R 1.63 R 1.69 
R 1.30 R 1.23 R 1.52 R 1.52 R 1.53 
- - - - - 
R 1.30 - - - - 
R 1.22 R 1.49 R 1.77 R 1.69 R 1.60 
- R 1.62 R 1.81 R 1.69 R 1.76 
Auro_Fluconazole 200mg Capsules 28 
Gulf_Fluconazole 200mg Capsules 28 
Flucoric 200mg Capsules 28 
Fluconazole - - - R 0.86 - 
- R 0.86 R 0.94 - - 
R 0.82 - - - - 
Nuzak 20mg Capsules 100 
Nuzak 20mg Capsules 28 
Nuzak 20mg Capsules 30 
Fluoxetine R 0.11 R 0.12 R 0.22 - - 
- R 0.14 R 0.21 - - 
R 0.12 - - - - 
Prolax 20mg Capsules 100 
Prolax 20mg Capsules 28 
 - - - R 0.20 R 0.20 
- - - R 0.20 R 0.20 
Bio-Glibenclamide 5mg Tablets 100 
Bio-Glibenclamide 5mg Tablets 28 
Bio-Glibenclamide 5mg Tablets 56 
Bio-Glibenclamide 5mg Tablets 84 
Glycomin 5mg Tablets 28 
Glycomin 5mg Tablets 56 
Glibenclamide R 0.07 R 0.07 R 0.11 R 0.10 R 0.09 
R 0.07 R 0.07 R 0.14 R 0.14 R 0.13 
R 0.07 R 0.04 R 0.11 R 0.10 R 0.09 
R 0.05 R 0.05 R 0.09 R 0.09 R 0.08 
R 0.08 R 0.07 R 0.14 R 0.14 R 0.14 
R 0.07 R 0.07 R 0.10 R 0.10 R 0.10 
Ridaq 25mg Tablets 28 
Ridaq 25mg Tablets 500 
Hydrochlorothiazide R 0.09 R 0.09 R 0.14 R 0.14 R 0.14 
- - R 0.13 R 0.13 R 0.13 
Adco-Lamivudine 150mg Tablets 56 
Aspen_Lamivudine 150mg Tablets 56 
Lamivudine R 0.29 R 0.44 R 0.49 R 0.46 R 0.47 
R 0.35 R 0.29 R 0.32 R 0.30 R 0.29 
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Cipla_Lamivudine 150mg Tablets 56 
Sonke_Lamivudine 150mg Tablets 56 
R 0.34 R 0.32 R 0.40 R 0.40 R 0.40 
R 0.35 R 0.39 R 0.44 R 0.41 R 0.43 
Adco-Loperamide 2mg Tablets 300 
Adco-Loperamide 2mg Tablets 6 
Cipla_Loperamide 2mg Tablets 8 
Loperamide - - R 0.07 R 0.07 R 0.07 
- - R 0.21 R 0.20 R 0.19 
R 0.11 R 0.13 - - - 
Austell-Losartan 50mg Tablets 28 
Ciplazar 50mg Tablets 30 
Losartan - - R 0.27 R 0.26 R 0.24 
R 0.21 R 0.21 - - - 
Austell_Metformin 500mg Tablets 56 
Austell_Metformin 500mg Tablets 84 
Forminal 500mg Tablets 56 
Forminal 500mg Tablets 84 
Indo_Metformin 500mg Tablets 56 
Indo_Metformin 500mg Tablets 84 
Mylan_Metformin 500mg Tablets 500 
Mylan_Metformin 500mg Tablets 84 
Metformin - - R 0.15 R 0.16 R 0.13 
- - R 0.15 R 0.14 R 0.13 
R 0.12 R 0.13 - - - 
R 0.12 R 0.13 - - - 
R 0.12 R 0.13 R 0.16 R 0.15 R 0.15 
R 0.11 R 0.09 - - - 
- - R 0.13 R 0.12 R 0.12 
- - R 0.15 R 0.14 R 0.14 
Ritalin 10mg Tablets 30 Methylphenidate R 0.82 R 0.82 R 0.82 R 0.82 R 0.83 
Adco-Contromet 10mg Tablets 10 
Adco-Contromet 10mg Tablets 100 
Bio_Metoclopramide 10mg Tablets 10 
Clomax 10mg Tablets 100 
Clomax 10mg Tablets 500 
Metoclopramide R 0.16 R 0.17 R 0.19 R 0.18 R 0.17 
- - R 0.08 R 0.08 R 0.07 
R 0.16 R 0.16 - - - 
R 0.05 R 0.05 - - - 
- - R 0.07 R 0.07 R 0.07 
ACRIPTAZ 200mg Tablets 56 
Adco-Nevirapine 200mg Tablets 56 
Aspen_Nevirapine 200mg Tablets 56 
Nevirapine R 0.38 R 0.57 R 0.68 R 0.65 R 0.61 
R 0.38 R 0.53 R 0.58 R 0.55 R 0.57 
R 0.39 R 0.54 R 0.59 R 0.56 R 0.54 
Bio-Nifedipine 10mg Capsules 100 Nifedipine R 0.49 R 0.49 R 0.56 R 0.53 R 0.50 
Epanutin 100mg Capsules 100 
Phenytoin 100mg Capsules 84 
Phenytoin_Sodium 100mg Tablets 84 
Phenytoin R 0.44 R 0.44 R 0.86 R 0.86 R 0.86 
- - R 0.73 R 0.72 R 0.59 
R 0.59 R 0.58 - - - 
Be-Tabs_Prednisone 5mg Tablets 100 
Be-Tabs_Prednisone 5mg Tablets 1000 
Be-Tabs_Prednisone 5mg Tablets 28 
Be-Tabs_Prednisone 5mg Tablets 500 
Be-Tabs_Prednisone 5mg Tablets 56 
Prednisone R 0.12 R 0.12 R 0.15 R 0.15 R 0.15 
- - - R 0.16 R 0.15 
R 0.12 R 0.12 R 0.15 R 0.15 R 0.15 
- - - R 0.16 R 0.15 
R 0.11 R 0.11 R 0.14 R 0.15 R 0.14 
Phenergan 25mg Tablets 100 Promethazine R 0.15 R 0.15 R 0.22 R 0.22 R 0.22 
Asthavent_Ecohaler 100mcg Inhaler 200 
Ventimax 100mcg Inhaler 200 
Salbutamol R 0.06 R 0.07 R 0.09 R 0.07 R 0.08 
R 0.08 R 0.08 R 0.10 R 0.08 R 0.08 
Aspen_Stavudine 30mg Capsules 56 
Sonke_Stavudine 30mg Capsules 56 
Stavudine - R 0.31 R 0.34 R 0.32 R 0.31 
R 0.27 - - - - 
Cipla-Zidovudine 100mg Capsules 100 
Zidomat 100mg Tablets 100 
Zidovudine R 0.43 - - - - 
- R 0.56 R 0.67 R 0.64 R 0.61 
 
 
[Table 2 contains medicine prices from the tender pricing system. There are prices for 
each branded medicine name for the corresponding year in the five-year period i.e. 
2014–2018. The letter R represents the South African currency in Rands] 
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Table 3: Single Exit Price (SEP) (per dosage form e.g. tablet/capsule/suspension) 
from 2014 to 2018 for the List of Medicines 
 
Manufacturer Product Name Active Ingredient 2014 
Price 
2015 
Price 
2016 
Price 
2017 
Price 
2018 
Price 
Acitab_200_DT 200mg Tablets 25 
Lovire 200mg Tablets 25 
Aciclovir - R 2.56 R 2.76 - - 
R 2.22 - - R 2.77 R 2.82 
Adco-Allopurinol 300mg Tablets 28 
Adco-Allopurinol 300mg Tablets 30 
Puricos 300mg Tablets 250 
Puricos 300mg Tablets 28 
Puricos 300mg Tablets 30 
Allopurinol - - - - - 
R 1.80 R 1.80 R 1.94 R 2.09 R 2.11 
R 1.80 - - - - 
- R 1.94 - - - 
R 1.80 - - - - 
Gulf_Amitriptyline 25mg Tablets 500 
Sandoz_Amitriptyline_HCL 25mg Tablets 100 
Sandoz_Amitriptyline_HCL 25mg Tablets 500 
Trepiline 25mg Tablets 100 
Trepiline 25mg Tablets 500 
Amitriptyline - R 0.54 R 0.58 R 0.63 R 0.64 
R 0.60 R 0.64 - - - 
R 0.54 R 0.58 - - - 
R 0.87 R 0.94 R 1.01 R 1.08 R 1.11 
R 0.87 - R 1.01 R 1.08 R 1.11 
Allmox 250mg Capsules 1000 
Allmox 250mg Capsules 500 
Amoxicap 250mg Capsules 500 
Amyn 250mg Capsules 500 
Austell_Amoxicillin 250mg Capsules 15 
Austell_Amoxicillin 250mg Capsules 500 
Moxymax 250mg Capsules 500 
Amoxicillin - - - R 0.37 R 0.37 
- - - R 0.37 R 0.37 
- R 0.32 R 0.34 - - 
R 0.33 - - - - 
- - - - R 0.00 
- - - R 0.59 - 
R 0.33 R 0.35 R 0.37 - - 
Austell_Atenolol 50mg Tablets 28 
Austell_Atenolol 50mg Tablets 30 
Austell_Tenopress 50mg Tablets 28 
Bio-Atenolol 50mg Tablets 30 
Zetenol 50mg Tablets 28 
Zetenol 50mg Tablets 30 
Atenolol R 0.66 - - - - 
R 0.66 - - - - 
- R 0.41 - - - 
R 0.55 R 0.59 R 0.64 R 0.69 R 0.70 
- - - R 0.65 - 
- - R 0.61 - R 0.67 
Beceze 50mcg Inhaler 200 
Beclate 50mcg Inhaler 200 
Beclometasone R 0.31 R 0.33 - - - 
- - R 0.39 R 0.42 R 0.43 
Bio-Captopril 25mg Tablets 60 Captopril R 0.29 R 0.32 R 0.34 R 0.37 R 0.37 
Degranol 200mg Tablets 100 
Gulf_Carbamazepine 200mg Tablets 84 
Carbamazepine R 1.89 R 2.04 R 2.20 R 2.36 R 2.41 
- - - - R 0.00 
Austell_Ceftriaxone 1g Vial 10 
Kocef-1000 1g Vial 3.5 
Rociject 1g Vial 3.5 
Ceftriaxone - R 2.40 R 2.59 - - 
R 16.30 R 17.52 R 18.89 R 20.31 R 20.75 
R 3.89 - - R 4.12 R 4.00 
Biotech_Ciprofloxacin 500mg Tablets 10 
Cifran 500mg Tablets 10 
Profloxin 500mg Tablets 10 
Ciprofloxacin R 1.72 R 1.85 R 1.99 - - 
- - - R 1.50 R 1.54 
R 2.11 R 2.27 R 2.37 R 2.55 R 2.61 
Auro_Amoxiclav 375mg Capsules 15 
Austell_Co-Amoxiclav 375mg Tablets 15 
Sandoz_Co-amoxyclav 375mg Tablets 100 
Sandoz_Co-amoxyclav 375mg Tablets 15 
Co-amoxiclav R 2.25 - - - - 
- - - R 2.75 R 2.81 
R 2.53 R 2.71 R 2.93 R 3.15 R 3.22 
R 2.58 R 2.76 R 2.98 R 3.21 R 3.27 
Doctrim 240mg/5ml Suspension 100 
Doctrim 240mg/5ml Suspension 50 
Ilvitrim_Suspension 240mg/5ml Suspension 100 
Ilvitrim_Suspension 240mg/5ml Suspension 50 
Ilvitrim_Suspension 240mg/5ml Suspension 500 
Co-trimoxazole R 0.08 R 0.08 R 0.09 R 0.10 R 0.10 
R 0.08 R 0.08 R 0.09 R 0.10 R 0.10 
R 0.08 R 0.09 R 0.09 R 0.10 R 0.10 
R 0.08 R 0.09 R 0.09 R 0.10 R 0.10 
R 0.08 R 0.09 R 0.09 R 0.10 R 0.10 
Betapam 5mg Tablets 1000 
Valium 5mg Tablets 100 
Diazepam R 0.09 R 0.09 - - - 
- - R 3.68 R 3.96 R 4.05 
Biotech_Diclofenac 25mg Tablets 500 R 0.13 R 0.14 - - - 
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Mylan_Diclofenac 25mg Tablets 500 Diclofenac - - R 0.15 R 0.15 R 0.15 
Adco-Efavirenz 600mg Tablets 30 
Cipla_Efavirenz 600mg Tablets 28 
Cipla_Efavirenz 600mg Tablets 30 
Efavirenz_Winthrop 600mg Tablets 28 
Efrin 600mg Tablets 28 
Efrin 600mg Tablets 30 
Sonke_Efavirenz 600mg Tablets 
28 Sonke_Efavirenz 600mg 
Tablets 30 
Efavirenz R 3.55 R 3.55 R 3.55 R 3.55 R 3.59 
- - - R 5.54 - 
R 4.45 R 4.78 R 5.15 - R 5.66 
R 5.94 - - - - 
- - - R 7.41 - 
R 5.95 R 6.39 R 6.89 - R 7.57 
- - - R 5.01 - 
- R 4.32 R 4.66 - R 3.26 
Nuzak 20mg Capsules 30 
Prolax 20mg Capsules 28 
Fluoxetine R 1.36 R 1.46 R 1.58 - - 
- - - R 0.94 R 0.96 
Bio-Glibenclamide 5mg Tablets 100 
Bio-Glibenclamide 5mg Tablets 500 
Glycomin 5mg Tablets 100 
Glycomin 5mg Tablets 30 
Glycomin 5mg Tablets 500 
Glibenclamide R 0.23 R 0.25 R 0.27 R 0.29 R 0.29 
R 0.23 R 0.25 R 0.27 - R 0.29 
R 0.24 R 0.25 R 0.27 R 0.29 R 0.30 
R 0.24 R 0.25 R 0.27 R 0.29 R 0.30 
R 0.24 R 0.25 R 0.27 R 0.29 R 0.30 
Ridaq 25mg Tablets 500 Hydrochlorothiazide R 0.82 R 0.88 R 0.95 R 1.03 R 1.05 
Adco-Lamivudine 150mg Tablets 60 
Aspen_Lamivudine 150mg Tablets 56 
Aspen_Lamivudine 150mg Tablets 60 
Cipla_Lamivudine 150mg Tablets 60 
Lamivudine R 0.70 R 0.70 R 0.70 R 0.70 R 0.71 
R 1.84 - - - - 
- R 1.98 R 2.13 R 2.29 R 2.34 
R 1.22 R 1.31 R 1.41 R 1.52 R 1.55 
Adco-Loperamide 2mg Tablets 300 
Adco-Loperamide 2mg Tablets 6 
Cipla_Loperamide 2mg Tablets 8 
Loperamide - - R 1.37 R 1.47 R 1.51 
- - R 1.37 R 1.47 R 1.51 
R 1.15 R 1.24 - - - 
Austell-Losartan 50mg Tablets 28 
Austell-Losartan 50mg Tablets 30 
Ciplazar 50mg Tablets 30 
Losartan - - - - R 3.20 
- - R 2.92 R 3.14 - 
R 2.93 R 3.15 - - - 
Austell_Metformin 500mg Tablets 100 
Austell_Metformin 500mg Tablets 500 
Forminal 500mg Tablets 100 
Forminal 500mg Tablets 500 
Forminal 500mg Tablets 60 
Indo_Metformin 500mg Tablets 100 
Indo_Metformin 500mg Tablets 500 
Mylan_Metformin 500mg Tablets 500 
Mylan_Metformin 500mg Tablets 90 
Metformin - - R 0.46 R 0.46 R 0.42 
- - R 0.46 R 0.46 R 0.42 
R 0.38 R 0.41 - - - 
R 0.38 R 0.41 - - - 
R 0.38 R 0.41 - - - 
R 0.36 R 0.38 R 0.40 R 0.43 R 0.44 
R 0.36 R 0.38 - - - 
- - R 0.40 R 0.43 R 0.44 
- - R 0.40 R 0.43 R 0.44 
Ritalin 10mg Tablets 30 Methylphenidate R 6.23 R 6.70 R 7.22 R 7.76 R 7.93 
Adco-Contromet 10mg Tablets 500 Metoclopramide R 0.11 R 0.12 R 0.13 R 0.14 R 0.14 
Bio_Metoclopramide 10mg Tablets 500 R 0.09 R 0.10 - - - 
Clomax 10mg Tablets 500 R 0.10 R 0.11 R 0.12 R 0.13 R 0.13 
ACRIPTAZ 200mg Tablets 56 Nevirapine - - - R 4.50 - 
ACRIPTAZ 200mg Tablets 60 R 3.61 R 3.88 R 4.18 - R 4.60 
Adco-Nevirapine 200mg Tablets 60 R 2.38 R 2.38 R 2.38 R 2.38 R 2.40 
Aspen_Nevirapine 200mg Tablets 56 - - - R 4.40 - 
Aspen_Nevirapine 200mg Tablets 60 R 3.61 R 3.88 R 4.19 - R 4.49 
Bio-Nifedipine 10mg Capsules 250 Nifedipine R 0.26 R 0.26 R 0.26 R 0.26 R 0.26 
Epanutin 100mg Capsules 100 Phenytoin R 2.26 R 2.43 R 2.50 R 2.68 R 2.74 
Phenytoin 100mg Capsules 100 - - R 0.56 - - 
Phenytoin 100mg Capsules 90 - - - R 0.60 R 0.62 
Phenytoin_Sodium 100mg Tablets 100 - R 0.52 - - - 
Phenytoin_Sodium 100mg Tablets 1000 R 0.48 - - - - 
Be-Tabs_Prednisone 5mg Tablets 1000 Prednisone R 0.12 R 0.16 R 0.17 R 0.20 R 0.21 
Phenergan 25mg Tablets 100 Promethazine R 1.13 R 1.21 R 1.31 R 1.40 R 1.43 
Asthavent_Ecohaler 100mcg Inhaler 200 R 0.12 R 0.13 R 0.13 R 0.14 R 0.15 
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Ventimax 100mcg Inhaler 200 Salbutamol R 0.13 R 0.13 R 0.14 R 0.16 R 0.16 
Aspen_Stavudine 30mg Capsules 56 Stavudine - - R 0.91 - - 
Aspen_Stavudine 30mg Capsules 60 - R 0.85 - R 0.98 R 1.00 
Sonke_Stavudine 30mg Capsules 60 R 0.54 - - - - 
Cipla-Zidovudine 100mg Capsules 100 Zidovudine R 1.94 - - - - 
Zidomat 100mg Tablets 100 - R 1.84 R 1.99 R 2.14 R 2.18 
 
 [Table 2 contains medicine prices per dosage form (e.g. tablet/capsule/suspension) 
from the SEP system. There are prices for each branded medicine name for the 
corresponding year in the five-year period i.e. 2014–2018. The letter R represents 
the South African currency in Rands] 
 
The first trend visually observed that medicine prices increased with time for both 
tender medicine prices and the SEP’s (found in 36 out of 74 branded medicine 
graphs). Trend lines were added to each branded medicine graph to assess the 
level of the price increase which was represented by the gradients of the slope (see 
Figure 1- Epanutin® 100mg tender gradient 0.126 and SEP gradient 0.121). 
 
 
Figure 1: Medicine prices of Epanutin® 100mg versus time 
[Figure 1 represents the price increases over the five-year period (2014–2018) for 
both tender (gradient 0.126) medicine prices and SEPs (gradient 0.121)  
The next trend visually displayed that the tender medicine prices for some branded 
medicine items remained the same or decreased in price for the five-year period, 
while the SEP’s for the same branded medicine increased. This was shown for 31 
of the total branded medicine graphs (see Figure 2- graph of Ritalin®10mg: gradient 
for tender 0.001 and gradient for SEP 0.447). 
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Figure 2: Medicine Prices of Ritalin®10mg versus time 
[Figure 2tender prices remained the same with time (2014–2018) while the SEP 
increased and is represented by medicine Ritalin®10mg- gradient for tender 0.001 
and gradient for SEP 0.447] 
 
The most prominent observation was that SEP’s were consistently higher than the 
tender medicine prices throughout the study period. The majority, 87.84% (65 out 
of 74), of the branded medicine items exhibited this behaviour (see Figure 3- graph 
of Bio-captopril® 25mg: gradient for tender 0.123 and gradient for  SEP 0.002). This 
was further substantiated by the price difference calculation that was computed. For 
the calculation between the two price systems to be completed, only 36 medicine 
brands could be used based on the calculation criteria (see method section). All 36 
items consistently showed higher SEP’s than tender prices during this observation. 
The lowest price difference was 33% (Be-tabs prednisone® 5mg) and the highest 
price difference was 1964.70% (Adco-loperamide® 2mg 300’s) shown in Error! R
eference source not found.. The median was 252.30% with quartile one at 94.75% 
and quartile two at 585.1%. The interquartile range was 490.35%. The dataset 
distribution was skewed to the right yielding a positive skewness.  
 
Figure 3:  Medicine prices (per tablet) of Bio-captopril®25mg versus time 
[Figure 3 represents the SEPs being more than tender price by the example of the 
medicine Bio-captopril®25mg- gradient of tender 0.123 and gradient of SEP 0.002] 
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Table 4: The Price Difference between Tender Price and SEP from 2014 to 2018 
Branded Medicine Name Price Difference 
Be-Tabs_Prednisone 5mg Tablets 1000 33.00% 
Doctrim 240mg/5ml Suspension 50 35.50% 
Austell_Co-Amoxiclav 375mg Tablets 15 46.00% 
Ilvitrim_Suspension 240mg/5ml Suspension 50 56.50% 
Doctrim 240mg/5ml Suspension 100 64.20% 
Ventimax 100mcg Inhaler 200 77.20% 
Asthavent_Ecohaler 100mcg Inhaler 200 79.70% 
Clomax 10mg Tablets 500 81.00% 
Mylan_Diclofenac 25mg Tablets 500 92.70% 
Ilvitrim_Suspension 240mg/5ml Suspension 100 96.80% 
Sandoz_Co-amoxyclav 375mg Tablets 15 108.90% 
Bio-Captopril 25mg Tablets 60 150.60% 
Beceze 50mcg Inhaler 200 153.20% 
Beclate 50mcg Inhaler 200 196.40% 
Bio-Glibenclamide 5mg Tablets 100 201.00% 
Cifran 500mg Tablets 10 213.80% 
Biotech_Ciprofloxacin 500mg Tablets 10 226.70% 
Zidomat 100mg Tablets 100 230.20% 
Mylan_Metformin 500mg Tablets 500 252.30% 
Profloxin 500mg Tablets 10 288.00% 
Epanutin 100mg Capsules 100 297.60% 
Adco-Allopurinol 300mg Tablets 30 361.90% 
Prolax 20mg Capsules 28 379.40% 
Acitab_200_DT 200mg Tablets 25 507.50% 
Lovire 200mg Tablets 25 540.90% 
Degranol 200mg Tablets 100 558.80% 
Gulf_Amitriptyline 25mg Tablets 500 576.00% 
Valium 5mg Tablets 100 581.60% 
Phenergan 25mg Tablets 100 588.60% 
Trepiline 25mg Tablets 100 604.60% 
Adco-Loperamide 2mg Tablets 6 630.90% 
Ridaq 25mg Tablets 500 666.10% 
Bio-Atenolol 50mg Tablets 30 702.30% 
Ritalin 10mg Tablets 30 771.80% 
Cipla_Loperamide 2mg Tablets 8 896.50% 
Ciplazar 50mg Tablets 30 1319.50% 
Adco-Loperamide 2mg Tablets 300 1964.70% 
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[Table 4 is the percentage price difference between the SEP and tender medicine 
prices for the period 2014–2018. The medicines are represented in their branded 
medicine name and the price difference is represented as a percentage.] 
 
The average price index (API) calculation was the final observation. From the basket 
of 32 active ingredients (with some brands having multiple pack sizes) only those 
items fitting the required criteria (see method section) were used in the calculation. 
The calculation was to establish the average price increase (in %) displayed by the 
specific medicine brand (in each pack size) within each price system. The purpose 
of displaying the data as such was to establish the price change patterns that could 
be observed in each respective price system. By virtue of differing data sets in each 
price system, annual price changes could not be compared directly between SEP 
and tender systems. The graph shows a more consistent price increase in the SEP 
system while the tender system showed a more sporadic price change pattern. In 
the tender system, 15 branded medicines (out of 47 brands) showed a price 
decrease while 32 showed an increase in price (see Figure 4).  Out of 81 branded 
medicines (overlapping brands for some medicines with multiple pack sizes) for the 
SEP system, 78 branded items demonstrated an increase in price while 3 branded 
items demonstrated a decrease. 
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Discussion 
Globally, medicine price regulations are implemented with the intent of containing 
medicine costs. In SA, the medicine price systems implemented differ across the 
private and public sectors. Despite both having the same intention of lowering 
medicine costs, the degree to which this is achieved requires further investigation.  
The article was thus written with the intent of identifying the price trends between 
the two systems by calculation of the price difference and price increases. 
At the outset, the study revealed that prices between the two healthcare sectors for 
the same medicine were glaringly different. Medicine prices in the private sectors 
were consistently higher than tender prices. This was similar to findings in other 
studies that proved tender medicine prices showed an overall decrease in medicine 
price [ (Baldi & Vannoni, 2015); (Bartels, 2016); (Bergman, et al., 2017); (Curto, et 
al., 2014); (Danzon, et al., 2015); (Kanavos, et al., 2009); (Petrou & Talias, 2014); 
(Raventos & Zolezzi, 2015) and (Wouters, et al., 2018)].  The most probable reason 
for this difference is the methodology adopted for the tendering process in the public 
sector.  This was elaborated upon in a  study by Wouters et al., which observed the 
impact of the tender medicine system in SA over a 14-year period: 2003–2016 
(Wouters, et al., 2018). According to Wouters et al. pharmaceutical tenders are 
bought after a confidential bidding process in bulk, usually from a central buyer 
which accounts for the fixed prices that are awarded (Wouters, et al., 2018). This 
indicates that the volumes procured largely influence the prices at which it will be 
available on the tender system. In the private sector, medicine prices are prohibited 
from being influenced by volume purchases by the price regulations applied. These 
regulations were permitted to improve price transparency in the private sector, 
especially where price negotiations (rebates and bonuses) promoted previous 
discounts from manufacturers to retailers and not awarded to patients.  
The selection criteria adopted in the tendering process could also attribute to the 
price differences seen in this study. The WHO defines the tendering process as a 
form of strategic purchasing based on several input factors (World Health 
Organization, 2020). Every country, therefore, establishes what factors strategically 
form their tender criteria. Competitive bidding (Dranitsaris, et al., 2017); (Kockaya & 
Wertheimer, 2016), price negotiations (The Department of Health ;, 2010), medicine 
efficacy, safety, quality and cost (Modisakeng, et al., 2020),are some of the factors 
used in the South African selection process. While these factors could be 
contributing to the low costs exhibited in the tender system as compared to the SEP 
system, there is no certainty that the tendering process has indeed led to the lowest 
possible prices.   In SA, the Government occasionally uses an ad hoc based criterion 
to promote local economic growth by favoring local manufactures for the tender 
(Wouters, et al., 2018). This indicates that the medicines supplied by the local 
manufacturers may not always be the most cost-effective, as seen in the Xiphu and 
Mpanza study where prices even in the public domain did not compare well with 
international reference prices or with prices in other African public sectors (Xiphu & 
Mpanza, 2004). Furthermore, the criteria for medicine selection for the EML was 
also identified as not being a completely transparent process (Perumal-Pillay & 
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Suleman, 2017). The tender process also has little coordination with regards to 
tender issuance and the registration of products, which leads to some items being 
excluded from tenders, further weakening competition (Wouters, et al., 2018). 
Therefore to maintain better competition among the drug companies, a better tender 
process needs to be developed to make it simpler for drug companies to participate 
in tenders (Wouters, et al., 2018). 
The tender process follows several selection criteria steps before concluding with a 
contract that is negotiated and agreed upon. Each contract contains all the details 
about the tender including the price, the duration of the contract, and even a section 
on price review rules (Department of Health, 2019). The price review section 
stipulates the conditions that will mandate a price change, which is mostly related 
to foreign exchange fluctuations (Department of Health, 2019). Foreign exchange 
rates affect the tender price especially when the medicine active ingredient is 
sourced internationally. This could be the reason for the sporadic price increases 
seen for the tender system in this study (see Figure 4). The graph showed irregular 
price increases for the tender system while the SEP system showed a steadier 
average price growth. The SEP system can account for the regular price increases 
as it is regulated by an annual price increase which is based on the CPI. Therefore, 
the private sector can account for the price increases seen because it is regulated 
tightly as compared to the public sector, which is not.   
The medicine price increases in the private system are capped thus providing an 
advantage. Before the SEP system was implemented, the price increases were 
much higher. In the Moodley and Suleman study, it was identified that there was an 
immediate decline in medicine prices after the implementation of the SEP system 
(Moodley & Suleman, 2019).  The yearly increases continued after the SEP 
regulation, however, the value by which it increased was regulated thus providing 
an overall decrease in medicine price in the private sector. This provided an 
advantage to the patients in the private sector as they were paying less in 
comparison to before the implementation of the SEP. However, in comparison to 
the prices available in the public sector, the private sector prices are vastly more 
The current study contained a basket of “lower-priced medicines” ( mostly generic 
brands) of which the price difference calculation yielded a median value of 
252.30%between SEP and tender prices with a positive skewness distribution There 
was a large distribution in price differences however the entire sample used for the 
calculation yielded positive values, which indicated that all the SEPs were higher 
than the tender prices for the sample used in the calculation. However a larger 
dataset is recommended to make inferential analysis., The price difference explored 
in the Wouters et al. study showed a 511% price difference for atorvastatin in 2009 
(Wouters, et al., 2018). This indicates that the yearly price increases have improved 
in the private sector but the price differences between the public and private sectors 
have not seen a significant change. 
While the tender system shows lower prices than the SEP system, it does face some 
limitations. These include an over or undersupply of medicines due to poor annual 
demand forecast estimations (Wouters, et al., 2018). Oversupply of medicines could 
lead to budget exhaustions (J, et al., 2010), while the undersupply of medicines lead 
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to medicine shortages (J, et al., 2010) (Wouters, et al., 2018). While budget 
exhaustions have serious implications, medicine shortages are a more common 
problem experienced in SA and other countries such as Netherlands (Kanavos, et 
al., 2009) and New Zealand (PHARMAC, 2016). A study conducted by Modisakeng 
et al. reviewed the medicine shortage problems in SA and concluded that the main 
challenges were in the procurement process (Modisakeng, et al., 2020). There are 
several adjustments to the tender structural approach (Management Sciences for 
Health, 2012) that can improve medicine shortages such as a split tender system. 
In SA, the split tender approach is utilized thus limiting the occurrence and impact 
of medicine shortages (Wouters, et al., 2018).  This approach is adopted to assist 
with volume issues especially when the needed product is of high importance such 
as first-line ARV drugs (Wouters, et al., 2018). This was the reason for several 
branded names being listed for one medicine active ingredient in this study (see 
Error! Reference source not found., Error! Reference source not found., and 
REF _Ref42443940 \h  \* MERGEFORMAT Error! Reference source not found.). 
It is noted that both tender and SEP systems have advantages and disadvantages. 
One downside of the SEP system is that there are additional costs applied to the 
SEP of a medicine in the form a dispensing fee (which a pharmacy may or may not 
apply) (Ondo, 2019). The price differences observed in the current study excluded 
the dispensing fees, which are governed by procedures that are weak and complex 
(Ondo, 2019), thus requiring further transparency and policy review. Ultimately the 
patient is paying more than the values identified in this study.  
The current study focused on establishing the differences between the price system 
in the private and public sectors. However, during the study, an underlying 
commonality was identified. Both the private and the public sectors underwent 
regulation changes to improve transparency, but complete transparency in these 
systems has not yet been achieved and should be improved. It is also recommended 
that as medicine procurement volume is a contributing factor in relation to price, and 
was not explored in this study, it should be further investigated.  
Limitations  
The medicines selected in the study were based on the WHO/HAI survey list  (Xiphu 
& Mpanza, 2004) and did not include all medicines that are on the tender. 
Generalizations for all medicines on the tender system therefore could not be made. 
The medicine list used in the study included mostly generic branded medicines 
(according to the tender awards) which show “lower-priced medicines” when 
compared to originator brands (higher medicine prices). Medicine prices were “low” 
in the study however it does not indicate that prices are generally low in SA but 
rather that the chosen list contained more “lower costing” medicines, which could 
bias the cost representations in the study. In the private sector the logistics fee is 
included as part of the SEP however, the logistics fee for medicines in the public 
sector were not reviewed in this study and should therefore be considered in future 
studies. The use of a larger dataset and inferential statistics would have 
strengthened the findings of this study.  
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Conclusion  
The trends depicted in the study showed that each price system does show some 
advantages and disadvantages. Varying price differences across both sectors is 
associated with a lack of transparency in establishing medicine prices. Therefore, 
to move towards a better-unified healthcare system (NHI), the underlying 
shortcomings in the current systems must be corrected. Policymakers need to 
ensure that a transparent system adheres throughout the medicine price processes 
in order to improve medicine price systems and healthcare in SA.  
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Supplementary Material 
Medicine basket selection flow chart
 
Final list of active ingredients used 
(32) 
(which are available in multiple branded 
medicine forms) 
 
 
Final list of branded medicines 
used (74) 
(One active ingredient could yield more 
than one available brand hence 74 
brands were used in the final list and not 
just 32). 
Essential Medicine List – in active 
ingredient form (42 active ingredients 
chosen) 
Availability of the active ingredient on 
the tender list in its branded medicine 
form in the five-year period (only 33 
active ingredients could be found and 
used from the original 42) 
 
Availability of the active ingredient 
(based on the tender list in its branded 
medicine form) on the SEP list for the 
five-year period (32 active 
ingredients) 
 
(An example of an active ingredient is 
paracetamol) 
(The active ingredient paracetamol can have more than one 
branded medicine form available on tender e.g. Panado® and 
Painblok®). 
 
(The active ingredient list yielded the final list of 
branded medicines to be used e.g. if active 
ingredient paracetamol was used and yielded only 
the brand Panado®, then that brand would make up 
the final branded medicine list) 
 
 
(If the active ingredient paracetamol was used 
and only available for the branded form 
Panado® on the SEP list, then the branded 
medicine Painblok® would have been excluded 
from the study. 
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Example of medicine basket selection process 
 
Paracetanol 
500mg
(active ingredient list)
Panado®
(branded medicine 
form)
Panado® price 
available on 
Tender list
Panado® price 
available on SEP 
list
makes up the final 
branded medicine list 
Painblok®
(branded medicine 
form)
excluded 
because the price 
was not available 
on both lists
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CHAPTER 4: CONCLUSION 
4.1 Introduction 
This study was carried out to establish the differences between medicine prices in the public 
and private healthcare sectors of South Africa (SA). The trend in medicine prices, as well as 
calculations of the price differentials and average price increases, were explored to determine 
the differences in each sector. The rationale for the study was to identify how current 
medicine pricing systems function in SA to make recommendations for future healthcare 
prospects in SA i.e. the NHI. From the medicine price differences explored during the study, 
it can be deduced that the pricing regulations largely influence the prices found in each 
sector. This study found that the medicine prices in the private sector were much higher 
relative to the public sector and requires elements of better system transparency to improve 
the current practices. 
4.1.1 Strengths of the Study Methodology and Design 
The gathering of the data was simple as each website forum allowed easy access to obtain 
the data. The data for five years were further categorised according to the research 
methodologies adopted with the relevant exclusion and inclusion criteria. Data were 
relatively easy to further analyse to deduce the trends and price differences for the two 
pricing systems investigated. 
4.1.2 Limitations of the Study 
• Prices were explored for selected medicines; therefore, the results of the study cannot be 
generalised. 
• The study contained a basket of “lower-priced medicines” (mostly generic brands used) 
and does not represent that all medicines in SA have low prices. 
4.2 Conclusions Drawn from the Study Findings 
This study aimed to compare the differences in medicine prices between the public and 
private healthcare sectors in SA i.e. the tender and SEP systems, respectively. The objectives 
of the study were to: 
1. identify the medicine pricing trends that exist 
2. determine the medicine price differential 
3. equate the average price index between each pricing system. 
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Conclusions drawn from the study findings based on the aforementioned objectives 
• Medicine prices in each system showed a general increase in medicine prices over the 
five-year period. 
• The most prominent observation was that medicine prices were higher in the SEP system 
as compared to the tender system as displayed in other studies (Wouters, et al., 2018). 
There were few exceptions for medicines in the tender system having higher prices than 
SEP however the majority displaying higher prices were found in the SEP system (87.84 
%). 
• The price differential calculation determined a median value of 252.30%   with 
distribution skewed to the right yielding a positive skewness. 
. There were no negative differential values found, indicating that all the medicine brands 
used in the average price differential calculation were always higher for the SEP than in 
the tender system. 
• Tender medicine prices decreased or remained the same for 41.89 % of the medicine 
brands explored, while the SEP for these same medicine brands increased. 
• The average price index (API) was calculated and extrapolated that medicine price 
increases for the tender system were changing in a more sporadic pattern. The price 
increases for the SEP system showed a steadier price change over the five-year period. 
The calculation showed that the tender system experienced more medicine price 
decreases in comparison to the SEP system that showed a majority of medicine prices 
increases. Thus, the patterns explored for the API are influenced by the regulations in 
place which affects the medicine price changes; in the case of the tender system the lack 
of such regulation whereas the SEP system that has a stricter price increase regulation. 
4.3 Significance of the Study 
• The results of the study indicate the medicine price differences that are experienced 
between the two medicine pricing systems in South Africa especially with a global goal 
of decreasing medicine costs (Volger, et al., 2017). 
• The two systems practice different pricing methodologies. Having explored the 
medicine prices for each system, a better understanding of the impact of the practices of 
each system has been gained. With the regulations in each system showing its influence 
on medicine prices, lack of transparency was a common trait identified in both systems. 
This finding can assist policymakers for future healthcare changes for SA, particularly 
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when the NHI is fully implemented. 
4.4 Recommendations 
• While each pricing system needs to update the methods used, a large part of improving 
the current systems, involves creating better transparency in all steps undertaken. The 
underlying problems faced in both systems included information gaps in several of the 
steps which impacted the prices of medicines in each sector. The tender system needs 
to focus on the approach for implementing price changes as well as the process for 
awarding tenders. 
• Policymakers need to re-evaluate the regulations implemented in the private sector. 
Regular amendments to the policies need to be considered at shorter intervals rather than 
longer, so that problem areas can be rectified, to avoid long-term impact. 
• Further studies are encouraged for a larger medicine basket selection to be able to 
generalise the study findings. 
• A thorough investigation of medicine price systems for the NHI needs to be conducted 
to be able to implement improved mechanisms for the new system. 
4.5 Chapter Summary 
This final chapter highlighted the conclusions drawn from the findings of the study and 
described the significance, strengths, and limitations of the study. It also provided 
recommendations for the problem areas identified in the study that need to be improved to 
enhance medicine pricing systems in SA. 
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